S&P Global Upgrades Biocon Biologics’ Credit Rating to ‘BB+’ with a Stable Outlook, Reports IndiaMedToday
S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics, a subsidiary of Biocon Limited, to ‘BB+’ from ‘BB’. The rating agency has also maintained a stable outlook for the company. This upgrade is a testament to Biocon Biologics’ strong business profile, driven by its robust product portfolio, expanding global presence, and significant investments in research and development.
The ‘BB+’ rating reflects Biocon Biologics’ established position in the biosimilars market, with a diverse portfolio of products across diabetes, oncology, and immunology. The company’s commitment to innovation and quality has enabled it to build a strong reputation in the industry. S&P Global Ratings noted that Biocon Biologics’ revenue growth is expected to remain robust, driven by the increasing demand for biosimilars globally.
The rating agency also highlighted the company’s improving profitability, driven by better operating efficiencies and a favorable product mix. Biocon Biologics’ EBITDA margin is expected to remain stable, supported by its ability to manage costs and maintain pricing power. The company’s debt-to-EBITDA ratio is expected to remain moderate, providing it with the flexibility to pursue growth opportunities.
The stable outlook reflects S&P Global Ratings’ expectation that Biocon Biologics will maintain its strong business profile, driven by its established product portfolio and expanding global presence. The company’s significant investments in research and development are expected to yield new product launches, further enhancing its competitive position.
The upgrade is a significant milestone for Biocon Biologics, as it reflects the company’s ability to execute its strategy and deliver strong financial performance. The ‘BB+’ rating will provide the company with better access to capital markets, enabling it to pursue its growth plans and expand its global footprint. Biocon Biologics’ strong ratings will also enhance its credibility with customers, partners, and investors, further solidifying its position as a leading player in the biosimilars market.
Overall, the rating upgrade by S&P Global Ratings is a testament to Biocon Biologics’ strong fundamentals and growth prospects. The company’s commitment to innovation, quality, and customer satisfaction has enabled it to establish a strong position in the industry, and the ‘BB+’ rating reflects its ability to maintain this position and pursue new opportunities for growth.
Hyderabad to Witness ‘Global Voices, One Vision’ International Health Dialogue 2026, Hosted by Apollo Hospitals
The 13th edition of the International Health Dialogue (IHD) will be hosted by Apollo Hospitals in Hyderabad on January 30 and 31, 2026. The event will bring together global leaders to discuss patient safety, healthcare innovation, and system-wide transformation. The theme of IHD 2026, “Global Voices. One Vision,” emphasizes the shared commitment to building resilient, patient-centric, and technology-enabled healthcare systems. The two-day program will focus on leadership-driven safety models, human-centered design, digital transformation, and excellence in hospital operations, patient experience, and clinical outcomes.
The event will feature four major conferences: the International Patient Safety Conference, Healthcare Operations & Patient Experience Conference, Transforming Healthcare with IT Conference, and CLINOVATE, which will focus on the future of laboratories and diagnostics in patient safety and clinical decision-making. Global policymakers, including ministers of health from Niger, Papua New Guinea, and the Republic of Congo, will participate in the conference, along with prominent international experts such as Dr. Jonathan Perlin and Dr. Carsten Engel.
The conference will also include innovative features such as Safe-A-Thon, a collaborative challenge to develop practical patient safety solutions, and the launch of THNX, India’s first digital health startup community. THNX will facilitate pitch sessions, funding opportunities, and investor interactions. The event is expected to reinforce India’s growing role as a hub for global healthcare thought leadership and innovation.
According to Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals Group, the International Health Dialogue has evolved into a dynamic global platform where clinicians, innovators, and policymakers come together to shape the future of healthcare. The Hyderabad edition of IHD 2026 will bring together the power of AI, data, and digital ecosystems with the timeless values of empathy and collaboration to make healthcare more predictive, sustainable, and inclusive. With plenary sessions, innovation showcases, and global networking forums, the event is expected to be a significant gathering of global healthcare leaders.
Sun Pharma receives green light for obesity treatment injection similar to Wegovy.
Sun Pharmaceutical Industries has received approval for a weight loss injection similar to Novo Nordisk’s Wegovy. The new treatment, called “SUN-144”, is a once-weekly injection that helps with weight management in adults with obesity or overweight with at least one weight-related condition. This approval marks a significant milestone for Sun Pharma, as it enters the growing market for anti-obesity treatments.
Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been highly successful in treating obesity, with sales exceeding $1 billion in 2022. SUN-144 is also a GLP-1 receptor agonist, which works by mimicking a natural hormone that helps regulate appetite and food intake. Clinical trials have shown that SUN-144 is effective in reducing body weight and improving glycemic control in patients with type 2 diabetes.
The approval of SUN-144 is expected to increase competition in the anti-obesity market, which is currently dominated by Novo Nordisk’s Wegovy and Saxenda. However, Sun Pharma’s entry into the market may also lead to increased accessibility and affordability of these treatments, which could benefit patients who struggle with obesity and related health conditions.
Sun Pharma’s SUN-144 has shown promising results in clinical trials, with significant weight loss and improvements in cardiovascular risk factors. The treatment has also been well-tolerated, with common side effects including nausea, vomiting, and diarrhea. As the global prevalence of obesity continues to rise, the demand for effective and safe treatments is increasing. Sun Pharma’s entry into the market is expected to help meet this demand and provide patients with more options for managing their weight and related health conditions.
The approval of SUN-144 is a significant achievement for Sun Pharma, which has been expanding its portfolio of specialty and generic products. The company has a strong presence in the pharmaceutical industry, with a global footprint and a wide range of products. With the launch of SUN-144, Sun Pharma is poised to become a major player in the anti-obesity market, which is expected to continue growing in the coming years. As the company prepares to launch SUN-144, it is likely to focus on educating healthcare professionals and patients about the benefits and risks of the treatment, as well as its potential to improve health outcomes for individuals with obesity and related conditions.
Lupin achieves top ESG rating from CDP for its efforts in addressing climate change and water security.
Lupin, a global pharmaceutical leader, has been recognized for its exceptional sustainability efforts, receiving the highest “A” leadership rating from the Climate Disclosure Project (CDP) for both Climate Change and Water Security. This prestigious recognition solidifies Lupin’s position among the world’s most sustainable and transparent companies. The double “A” rating reflects Lupin’s significant progress in mitigating climate risks, reducing carbon emissions, and ensuring responsible water management across its operations.
Compared to its previous ratings, Lupin has made substantial improvements, upgrading from “A-” in 2024 and “B” and “C” in 2023 for climate and water, respectively. This remarkable achievement demonstrates Lupin’s commitment to sustainability and its proactive initiatives to minimize its environmental impact. Ramesh Swaminathan, Executive Director and Global CFO, expressed pride in earning the double “A” rating, attributing it to the company’s innovative approaches, collaborative efforts, and transparent practices.
Lupin’s sustainability endeavors have also been recognized by S&P Global, which awarded the company an ESG score of 91 in 2025. This achievement places Lupin among an elite group of companies worldwide that have surpassed the 90-point threshold, demonstrating its best-in-class sustainability performance. The CDP’s strict framework has played a significant role in shaping and accelerating Lupin’s climate initiatives, driving ongoing progress and commitment to establishing new sustainability standards.
The recognition from CDP and S&P Global underscores Lupin’s dedication to generating lasting value for its communities and the planet. As a global pharma leader, Lupin is committed to reducing its environmental impact through innovation, collaboration, and transparency, setting a high standard for sustainability in the industry. With its exceptional achievements, Lupin continues to demonstrate its position as a responsible and sustainable business leader, driving positive change and promoting a more environmentally conscious future.
Zydus Lifesciences introduces India’s first biosimilar version of Nivolumab, a global breakthrough.
Zydus Lifesciences, a leading life sciences company, has launched the world’s first biosimilar of nivolumab in India under the brand name Tishtha. This milestone marks a significant expansion of patient access to cutting-edge cancer therapies, particularly in the field of Immuno-Oncology. Tishtha will be available in two dosage strengths, 100 mg and 40 mg, priced at ₹28,950 and ₹13,950, respectively, which is approximately one-fourth of the reference product. This competitive pricing aims to improve treatment affordability and reduce the financial burden of cancer treatment.
The launch of Tishtha reinforces Zydus Lifesciences’ commitment to patient-centric care, with a focus on providing timely access to affordable and advanced cancer care. The company aims to support patients throughout their treatment journey, ensuring consistency, affordability, and reach. The development and manufacturing of Tishtha in India ensures long-term supply reliability, enabling patients to continue therapy without disruption.
The introduction of Tishtha in India significantly broadens access to advanced Immuno-Oncology treatments, making high-quality biosimilar immunotherapies accessible to a wider patient population. This launch is a pivotal step in Zydus Lifesciences’ efforts to make innovative, affordable healthcare solutions available to patients. By providing a reliable and consistent supply of Tishtha, the company aims to reduce clinical risk and financial stress associated with treatment interruptions.
According to Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences, every patient deserves timely access to affordable and advanced cancer care. The company’s commitment to patient access and affordability is reflected in the pricing of Tishtha, which is designed to minimize drug wastage and optimize dosing. With the launch of Tishtha, Zydus Lifesciences continues to play a leading role in advancing patient-centric Immuno-Oncology care in India, providing patients with access to innovative and affordable treatment options.
India’s Path To Universal Health Care Outlined In Lancet Paper Ahead Of Budget 2026 – BW Healthcare World
A recent paper published in The Lancet has outlined a roadmap for India to achieve universal health care by 2030, with a focus on the upcoming Budget 2026. The paper, titled “India’s path to universal health coverage: a call to action,” highlights the country’s progress towards achieving universal health care and identifies key areas that require attention and investment.
The authors of the paper note that India has made significant strides in improving health outcomes in recent years, with a decline in infant and maternal mortality rates, and an increase in life expectancy. However, despite these gains, the country still faces significant health challenges, including a high burden of non-communicable diseases, inadequate healthcare infrastructure, and a shortage of healthcare professionals.
To address these challenges, the paper recommends that the Indian government increase its investment in healthcare to at least 2.5% of the country’s GDP by 2025, with a focus on strengthening primary healthcare, improving healthcare infrastructure, and enhancing the skills of healthcare professionals. The authors also emphasize the need for a more equitable and inclusive healthcare system, with a focus on reaching marginalized and vulnerable populations.
The paper identifies several key areas that require attention and investment in the upcoming Budget 2026, including:
- Strengthening primary healthcare: The authors recommend increasing investment in primary healthcare, including the expansion of health and wellness centers, and the deployment of more community health workers.
- Improving healthcare infrastructure: The paper highlights the need for significant investment in healthcare infrastructure, including the construction of new hospitals, the upgrading of existing facilities, and the procurement of medical equipment.
- Enhancing the skills of healthcare professionals: The authors recommend increasing investment in the training and development of healthcare professionals, including doctors, nurses, and community health workers.
- Expanding health insurance coverage: The paper emphasizes the need to expand health insurance coverage to all citizens, with a focus on marginalized and vulnerable populations.
Overall, the paper provides a comprehensive roadmap for India to achieve universal health care by 2030, with a focus on strengthening primary healthcare, improving healthcare infrastructure, and enhancing the skills of healthcare professionals. The authors emphasize the need for significant investment in healthcare in the upcoming Budget 2026, and highlight the importance of a more equitable and inclusive healthcare system that reaches all citizens, regardless of their income or social status.
Glenmark introduces emergency epinephrine injection – Drug Store News
Glenmark Pharmaceuticals has launched an epinephrine injection, which is the first FDA-approved generic version of Auvi-Q, according to a report by Drug Store News. The epinephrine injection, also known as epinephrine injection, USP, is a prescription medication used to treat life-threatening allergic reactions, including anaphylaxis.
The medication is available in a pre-filled syringe and is administered via intramuscular injection, typically in the middle of the outer thigh. It is designed to provide fast and effective relief from severe allergic reactions, which can be caused by a range of allergens, including food, insect stings, and latex.
The launch of the epinephrine injection by Glenmark is significant, as it provides patients with a more affordable alternative to branded products. The list price of Glenmark’s epinephrine injection is expected to be lower than that of Auvi-Q, making it a more accessible option for patients who require this life-saving medication.
Glenmark’s epinephrine injection has been approved by the FDA in two doses: 0.3mg and 0.15mg. The 0.3mg dose is intended for patients who weigh 30kg or more, while the 0.15mg dose is intended for patients who weigh between 15kg and 30kg. The medication is available in a carton of two auto-injectors, each containing a single dose of epinephrine.
The launch of Glenmark’s epinephrine injection is an important development for patients who are at risk of anaphylaxis. Anaphylaxis is a severe and potentially life-threatening allergic reaction that requires immediate medical attention. Symptoms of anaphylaxis can include difficulty breathing, rapid heartbeat, and a drop in blood pressure. If left untreated, anaphylaxis can lead to serious health consequences, including death.
Glenmark’s epinephrine injection provides patients with a reliable and effective treatment option for anaphylaxis. The medication has undergone rigorous testing and has been shown to be safe and effective in clinical trials. With its launch, Glenmark is helping to expand access to this critical medication, making it more widely available to patients who need it.
Overall, the launch of Glenmark’s epinephrine injection is a significant development in the treatment of anaphylaxis. The medication provides patients with a fast and effective treatment option for severe allergic reactions, and its availability is expected to improve health outcomes for patients who are at risk of anaphylaxis.
Several major Indian pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti, have issued recalls for certain medications in the United States market.
Several major pharmaceutical companies, including Sun Pharma, Cipla, Zydus, and Graviti Pharmaceuticals, are recalling various products in the US due to manufacturing issues, according to recent US FDA enforcement reports. The recalls are primarily related to problems with impurities, quality control, and production processes.
Sun Pharma is recalling over 24,000 bottles of Fluocinolone Acetonide topical solution and Clindamycin Phosphate topical solution due to out-of-specification results for impurities and assay. Cipla is recalling more than 15,000 syringes of Lanreotide Injection, used to treat a rare hormonal condition, due to production issues at its Greek manufacturing partner, Pharmathen. The production of Lanreotide has been temporarily paused to address quality concerns, resulting in limited supply.
Additionally, Cipla is recalling over 92,000 tubes of Diclofenac Sodium Topical Gel due to failed pH specifications. Graviti Pharmaceuticals is recalling over 4,000 bottles of Furosemide Tablets due to the presence of a foreign substance. Zydus Pharmaceuticals is recalling over 22,000 bottles of Icosapent Ethyl capsules due to oxidation caused by leakage, which may lead to inconsistent therapeutic effects and increased gastrointestinal side effects.
These recalls highlight the importance of quality control and manufacturing standards in the pharmaceutical industry. The FDA’s enforcement actions aim to ensure that products meet strict safety and efficacy standards to protect public health. The recalls may result in temporary shortages of these products, and patients are advised to consult their healthcare providers for alternative treatments.
The recalls also underscore the need for pharmaceutical companies to maintain robust quality control systems and adhere to good manufacturing practices (GMPs) to prevent such issues. The companies involved are taking corrective actions to address the problems and prevent future occurrences. The FDA will continue to monitor the situation and take further action if necessary to ensure the safety and efficacy of pharmaceutical products in the US market.
According to Apollo doctor, adopting three key lifestyle modifications can significantly safeguard cardiovascular well-being and reduce the risk of developing high blood pressure naturally.
High blood pressure, or hypertension, is a significant risk factor for cardiovascular disease, which is the leading cause of death worldwide. According to the World Health Organization (WHO), approximately 1.13 billion people globally suffer from hypertension, and this number is expected to increase to 1.5 billion by 2025. In an effort to mitigate this risk, a doctor from Apollo Hospital has recommended three essential lifestyle changes to protect heart health and naturally lower the risk of high blood pressure.
Firstly, the doctor emphasizes the importance of maintaining a healthy diet. A well-balanced diet rich in fruits, vegetables, whole grains, and lean proteins can help regulate blood pressure. Specifically, the doctor recommends consuming foods that are high in potassium, such as bananas, leafy greens, and sweet potatoes, as potassium helps to lower blood pressure by balancing out the effects of sodium in the body. Additionally, reducing sodium intake and limiting the consumption of processed and packaged foods is crucial in maintaining healthy blood pressure levels.
Secondly, regular physical activity is vital for heart health. Engaging in at least 150 minutes of moderate-intensity aerobic exercise, such as brisk walking, cycling, or swimming, or 75 minutes of vigorous-intensity aerobic exercise, such as running or HIIT (High-Intensity Interval Training), per week can significantly lower blood pressure. The doctor also recommends incorporating strength training exercises into one’s routine, as this can help improve overall cardiovascular health and reduce the risk of hypertension.
Lastly, managing stress is essential for maintaining healthy blood pressure levels. Chronic stress can lead to increased blood pressure, and the doctor recommends practicing stress-reducing techniques such as meditation, yoga, or deep breathing exercises. Getting adequate sleep, ideally 7-8 hours per night, is also crucial in regulating blood pressure and overall cardiovascular health.
In conclusion, making these three lifestyle changes can significantly reduce the risk of high blood pressure and promote overall heart health. By adopting a balanced diet, engaging in regular physical activity, and managing stress, individuals can naturally lower their blood pressure and reduce their risk of cardiovascular disease. The doctor emphasizes that these changes are simple yet effective and can be incorporated into one’s daily routine with minimal effort. By taking control of one’s lifestyle, individuals can take a proactive approach to protecting their heart health and reducing their risk of hypertension.
Lupin Achieves Prestigious CDP Double ‘A’ Rating for Excellence in Climate Change Mitigation and Water Stewardship
Lupin, a global pharmaceutical company, has achieved a significant milestone in its sustainability journey by earning a double ‘A’ rating from CDP (formerly known as the Carbon Disclosure Project) for its leadership in climate action and water security. This prestigious rating recognizes Lupin’s efforts to reduce its environmental impact and mitigate the risks associated with climate change and water scarcity.
CDP is a non-profit organization that assesses companies’ environmental performance and transparency. The double ‘A’ rating is the highest rating given by CDP, and it indicates that Lupin has demonstrated exceptional leadership and commitment to environmental stewardship. Lupin is one of only a few companies globally to achieve this rating, and it is a testament to the company’s dedication to sustainability.
Lupin’s climate action efforts have focused on reducing greenhouse gas emissions, transitioning to renewable energy sources, and implementing energy-efficient technologies. The company has set ambitious targets to reduce its carbon footprint, including a goal to become carbon neutral by 2050. Lupin has also implemented various initiatives to promote sustainable practices throughout its supply chain, including working with suppliers to reduce their environmental impact.
In addition to its climate action efforts, Lupin has also demonstrated leadership in water security. The company has implemented water conservation measures across its operations, including rainwater harvesting and wastewater treatment. Lupin has also engaged with local communities to promote water conservation and support watershed development projects.
The double ‘A’ rating from CDP is a significant achievement for Lupin, and it reflects the company’s commitment to sustainability and environmental responsibility. Lupin’s leadership in climate action and water security will not only reduce its environmental impact but also contribute to the well-being of local communities and the planet as a whole. The company’s sustainability efforts are aligned with the United Nations’ Sustainable Development Goals (SDGs), and it is working to integrate the SDGs into its business strategy.
Overall, Lupin’s double ‘A’ rating from CDP is a testament to the company’s dedication to sustainability and environmental stewardship. The company’s efforts to reduce its environmental impact and promote sustainable practices will have a positive impact on the environment, local communities, and its business operations. As a responsible corporate citizen, Lupin is committed to continuing its sustainability journey and making a positive difference in the world.
Bengaluru to host Zydus Pinkathon after a 7-year hiatus
The Zydus Pinkathon, a prominent women’s running event, is set to return to Bengaluru on January 25, marking its eighth edition in the city after a seven-year hiatus. With an expected participation of over 5,000 women, the event aims to promote fitness and community engagement among women of all age groups and fitness levels. The event will feature various race categories, including 3 km, 5 km, and 10 km runs, as well as ultradistances of 50 km, 75 km, and 100 km, and a 100 km relay.
The Bengaluru edition is being supported by the Department of Youth Empowerment and Sports, Government of Karnataka, and has received institutional backing from the Sports Authority of India and Fit India. The event is designed to encourage women to adopt regular physical activity, particularly in a city like Bengaluru, which is known for its young, working population and high-pressure lifestyles.
Founded by Milind Soman in 2012, Pinkathon has positioned Bengaluru as a key city in its journey, citing the city’s strong running culture and growing focus on wellness. The event has become a significant part of the city’s fitness landscape, and its return is expected to be a major boost to the city’s running community.
The Zydus Pinkathon is part of the 2025-26 nationwide season, which will also include events in Hyderabad on February 15 and Delhi on March 8. The event’s organizers aim to use the platform to promote fitness-led community engagement and encourage women to prioritize their physical and mental well-being. With its diverse range of race categories and inclusive approach, the Zydus Pinkathon is expected to be a memorable and empowering experience for all participants. Overall, the return of the Zydus Pinkathon to Bengaluru is a significant development for the city’s fitness enthusiasts and a testament to the growing importance of women’s health and wellness in India.
Glenmark Pharmaceuticals Names Neha Jangale as New Head of Learning and Development
Glenmark Pharmaceuticals, a leading global pharmaceutical company, has announced the appointment of Neha Jangale as the Head of Learning and Development (L&D). This strategic move aims to further strengthen the company’s commitment to employee development and growth.
Neha Jangale, with her extensive experience in the field of human resources, will be responsible for designing and implementing comprehensive learning and development programs across the organization. Her primary focus will be on creating a culture of continuous learning, enabling employees to acquire new skills, and enhancing their overall performance.
In her new role, Neha will work closely with the leadership team to identify skill gaps and develop targeted training programs to address these gaps. She will also be responsible for creating a robust framework for leadership development, succession planning, and talent management. Her expertise will help in creating a learning ecosystem that supports the company’s business objectives and fosters a culture of innovation and excellence.
Neha’s appointment is a testament to Glenmark’s commitment to investing in its employees and creating a work environment that encourages growth and development. The company recognizes that its employees are its most valuable assets and is dedicated to providing them with the necessary tools and resources to succeed.
Glenmark Pharmaceuticals has a strong track record of developing and implementing innovative L&D programs. The company has a dedicated L&D team that works closely with various stakeholders to design and deliver programs that cater to the diverse needs of its employees. With Neha at the helm, the company is expected to take its L&D initiatives to the next level, focusing on creating a more agile, adaptable, and future-ready workforce.
The appointment of Neha Jangale as the Head of L&D is a significant step forward for Glenmark Pharmaceuticals. Under her leadership, the company is poised to create a learning culture that is aligned with its business strategy and supports the growth and development of its employees. As the pharmaceutical industry continues to evolve, Glenmark is well-positioned to stay ahead of the curve, driven by a talented and skilled workforce. With Neha’s expertise and passion for L&D, the company is expected to achieve its vision of becoming a leading global pharmaceutical company.
Delhi High Court Dismisses Alkem’s Bid to Trademark ‘A TO Z’
The Delhi High Court has rejected a trademark claim by Alkem Laboratories, a pharmaceutical company, over the use of the term “A TO Z” for its products. The court ruled that alphabets are public property and cannot be monopolized by a single entity.
Alkem Laboratories had filed a lawsuit against another pharmaceutical company, Unichem Laboratories, alleging that Unichem’s use of the term “A TO Z” for its products infringed on Alkem’s trademark. Alkem claimed that it had been using the term “A TO Z” for its products since 1972 and had acquired a reputation and goodwill in the market.
However, the court rejected Alkem’s claim, stating that alphabets are public property and cannot be trademarked. The court observed that the term “A TO Z” is a common phrase used to denote a comprehensive range of products or services, and its use by Unichem did not infringe on Alkem’s trademark.
The court also noted that Alkem had not provided sufficient evidence to prove that its use of the term “A TO Z” had acquired a distinctive character and was exclusively associated with its products. The court held that the term “A TO Z” is a descriptive phrase and not a distinctive trademark.
The judgment is significant as it sets a precedent for the use of common phrases and alphabets in trademarks. It emphasizes that companies cannot claim exclusive rights over public property, such as alphabets, and that trademark law is intended to protect distinctive signs and symbols that identify a particular business or product.
The court’s decision is also a victory for Unichem Laboratories, which can continue to use the term “A TO Z” for its products without fear of infringement. The judgment highlights the importance of ensuring that trademark claims are not used to stifle competition or restrict the use of common language.
In conclusion, the Delhi High Court’s rejection of Alkem’s trademark claim over the term “A TO Z” is a significant ruling that emphasizes the public nature of alphabets and common phrases. The judgment sets a precedent for the use of trademarks and highlights the importance of protecting distinctive signs and symbols that identify a particular business or product.
Lupin Earns Top CDP A Rating for Efforts in Combating Climate Change and Conserving Water
Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest ‘A’ leadership rating from the Climate Disclosure Project (CDP) for its exceptional performance in Climate Change and Water Security. This recognition is a testament to Lupin’s commitment to sustainability and transparency, placing the company among the world’s leading organizations that prioritize environmental stewardship.
Lupin’s double ‘A’ rating in Climate and Water demonstrates its proactive approach to mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations. This achievement represents a significant improvement from the company’s previous ratings, with a substantial enhancement from ‘A-‘ in 2024 and ‘B’ in 2023 for climate, and ‘C’ for water. This progress reflects Lupin’s dedication to continuous improvement and its efforts to establish new sustainability standards.
The company’s Executive Director, Ramesh Swaminathan, attributed this achievement to Lupin’s innovative approaches, collaborative efforts, and transparency. He emphasized that the CDP’s framework has helped shape and accelerate the company’s climate initiatives, driving ongoing progress. Lupin’s commitment to sustainability is also reflected in its S&P Global ESG score of 91 in 2025, which is a best-in-class global achievement. This score positions Lupin among a select group of companies worldwide that have surpassed the 90-point threshold, demonstrating its exceptional performance in environmental, social, and governance (ESG) aspects.
Lupin’s achievement is a significant milestone in the pharmaceutical industry, highlighting the company’s dedication to reducing its environmental impact while generating lasting value for its communities and the planet. By prioritizing sustainability and transparency, Lupin is setting a high standard for the industry and demonstrating its commitment to creating a better future for all stakeholders. Overall, Lupin’s double ‘A’ rating from CDP and its exceptional ESG score are a testament to the company’s leadership in sustainability and its efforts to make a positive impact on the environment.
US FDA Concludes Inspection at Zydus’ Ankleshwar Facility with Three Noted Observations.
The US Food and Drug Administration (USFDA) has completed an inspection at Zydus Cadila’s manufacturing facility in Ankleshwar, Gujarat, with three observations. The inspection was conducted from February 13 to February 17, 2023. Although the company has not provided detailed information about the observations, it has stated that they are not related to data integrity or repeat observations from previous inspections.
The Ankleshwar plant is a key manufacturing facility for Zydus Cadila, producing a range of pharmaceutical products, including injectables, oral solids, and topical formulations. The USFDA inspection is a critical step in ensuring compliance with regulatory requirements for products exported to the US market. The observations made by the USFDA are considered minor, and the company is expected to respond to them within a specified timeframe.
Zydus Cadila has a history of USFDA inspections at its various manufacturing facilities. In 2020, the company’s Moraiya facility received a warning letter from the USFDA, citing several observations related to quality control and manufacturing practices. However, the company has since taken corrective actions and has been working to improve its compliance with regulatory requirements.
The outcome of the recent inspection at the Ankleshwar plant is seen as a positive development for Zydus Cadila, as it indicates that the company is on the right track in terms of compliance with USFDA regulations. The company’s management has stated that it is committed to maintaining high standards of quality and compliance at all its manufacturing facilities.
The inspection outcome is also significant for the Indian pharmaceutical industry as a whole, as it demonstrates the country’s ability to produce high-quality pharmaceutical products that meet international regulatory standards. India is a major player in the global pharmaceutical industry, with many companies exporting products to the US and other countries.
In conclusion, the USFDA’s inspection at Zydus Cadila’s Ankleshwar plant with three observations is a positive development for the company and the Indian pharmaceutical industry. While the observations are minor, the company will need to respond to them promptly to ensure compliance with regulatory requirements. The inspection outcome highlights the importance of maintaining high standards of quality and compliance in the pharmaceutical industry, and Zydus Cadila’s commitment to these principles is expected to support its growth and success in the global market.
A recall has been issued for a batch of MS medication after it was found that the capsules were dissolving at a slower rate than expected.
A batch of a multiple sclerosis (MS) medication has been recalled due to a manufacturing issue that affects the dissolution of the capsules. The medication, called Copaxone, is a glatiramer acetate injection used to treat relapsing forms of MS. The recall was initiated by the manufacturer, Teva Pharmaceuticals, after it was discovered that some capsules may not be dissolving at the expected rate.
The issue was identified during routine testing, which revealed that some capsules were not meeting the required dissolution specifications. As a result, Teva Pharmaceuticals has recalled the affected batch, which was distributed in the UK and other countries. The company has stated that the recall is a precautionary measure to ensure the quality and efficacy of the medication.
The slow dissolution of the capsules may affect the release of the active ingredient, glatiramer acetate, which could potentially impact the medication’s effectiveness in managing MS symptoms. However, Teva Pharmaceuticals has emphasized that there is no evidence to suggest that the affected batch poses a safety risk to patients.
Patients who are currently taking Copaxone are advised to check their medication packaging to see if it is part of the recalled batch. The affected batch numbers and expiry dates can be found on the Medicines and Healthcare products Regulatory Agency (MHRA) website. If a patient has a recalled batch, they should contact their pharmacist or healthcare provider for advice on what to do next.
Teva Pharmaceuticals has assured patients that alternative supplies of Copaxone are available, and that they are working to rectify the issue as quickly as possible. The company has also stated that it is cooperating fully with regulatory authorities to resolve the issue.
The recall highlights the importance of quality control measures in the pharmaceutical industry. Regular testing and inspection of medications are crucial to ensuring that they meet the required standards of quality, safety, and efficacy. The MHRA has stated that it is monitoring the situation closely and will take further action if necessary to protect public health.
In the meantime, patients with MS are advised to continue taking their medication as prescribed, unless advised otherwise by their healthcare provider. If patients have any concerns or questions about the recall, they should contact their pharmacist or healthcare provider for guidance and support.
Lupin Achieves Top ESG Score from CDP for Efforts in Combating Climate Change and Ensuring Water Security – Reported by Chennai Patrika.
Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest ‘A’ leadership rating from the Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. This recognition solidifies Lupin’s position as a global leader in championing sustainability and transparency. The company’s double ‘A’ rating in Climate and Water is a testament to its commitment to mitigating climate risks, reducing carbon emissions, and ensuring responsible water management throughout its operations.
This achievement represents a substantial improvement from Lupin’s previous ratings, with the company moving from ‘A-‘ in 2024 to ‘A’ in 2025, and from ‘B’ in 2023 to ‘A’ in 2025 for climate and water, respectively. This significant year-over-year progress demonstrates Lupin’s dedication to sustainability and its proactive initiatives aimed at reducing its environmental impact.
Ramesh Swaminathan, Executive Director, Global CFO and Head of API Plus SBU at Lupin, expressed pride in the company’s achievement, stating that Lupin has advanced its efforts to reduce environmental impact through innovation, collaboration, and transparency. He also acknowledged the role of CDP’s strict framework in shaping and accelerating the company’s climate initiatives, fostering ongoing progress.
In addition to the CDP rating, Lupin has also achieved an S&P Global ESG score of 91 in 2025, a best-in-class global achievement that positions the company among a distinguished group of companies worldwide that have surpassed the 90-point threshold. This recognition demonstrates Lupin’s commitment to establishing new sustainability standards and generating lasting value for its communities and the planet. Overall, Lupin’s achievements in sustainability and environmental responsibility underscore its position as a responsible and forward-thinking global pharmaceutical leader.
Sun Pharma receives DCGI approval for generic version of Wegovy, plans March release ahead of Semaglutide patent expiration.
Sun Pharmaceutical Industries has received approval from the Drugs Controller General of India (DCGI) to launch a generic version of Novo Nordisk’s Wegovy, a medication used to treat obesity. The approval comes as the patent for the active ingredient, semaglutide, is set to expire in March 2023.
Wegovy, which contains semaglutide, is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist that helps with weight loss in adults with obesity. The medication has been shown to be effective in reducing body weight and improving glycemic control in patients with type 2 diabetes.
Sun Pharma’s generic version of Wegovy will be launched in India in March, coinciding with the patent expiry of semaglutide. The company has been working on developing a generic version of the medication for some time and has completed the necessary clinical trials and regulatory requirements to obtain approval from the DCGI.
The launch of Sun Pharma’s generic Wegovy is expected to increase access to this medication for patients in India, where obesity is a growing health concern. According to the World Health Organization (WHO), India has one of the highest rates of obesity in the world, with over 30% of the population classified as obese.
The generic version of Wegovy is also expected to be more affordable than the branded version, making it more accessible to patients who may not have been able to afford the medication otherwise. Sun Pharma’s entry into the market is likely to increase competition and drive down prices, benefiting patients and healthcare systems.
Novo Nordisk’s Wegovy has been a blockbuster medication, with sales of over $1 billion in 2022. The patent expiry of semaglutide is expected to lead to a significant increase in the availability of generic versions of the medication, which could impact Novo Nordisk’s sales. However, the company has a strong pipeline of new medications and is expected to continue to be a major player in the pharmaceutical industry.
Overall, the approval of Sun Pharma’s generic Wegovy is a significant development for patients in India, who will now have access to an affordable and effective treatment option for obesity. The launch of the generic medication is also expected to increase competition in the market, driving down prices and benefiting healthcare systems.
Alkem Laboratories slapped with ₹2.35 crore GST demand notice and penalty by Additional Commissioner, as reported by scanx.trade
Alkem Laboratories, a prominent Indian pharmaceutical company, has received a Goods and Services Tax (GST) demand order from the Additional Commissioner, totaling ₹2.35 crore, along with a penalty. The order, which was issued on [date], has sparked concerns among the company’s stakeholders and has the potential to impact its financial performance.
The GST demand order pertains to the period between [date] and [date], during which the company allegedly failed to pay the required GST on certain transactions. The Additional Commissioner has calculated the total tax liability to be ₹2.35 crore, which includes both the principal amount and the applicable interest.
In addition to the tax demand, the company has also been slapped with a penalty for non-compliance with GST regulations. The penalty amount, which is a significant portion of the total demand, is intended to deter companies from evading taxes and to ensure that they adhere to the tax laws.
Alkem Laboratories has stated that it is reviewing the GST demand order and will take necessary actions to address the issue. The company may choose to appeal against the order, or it may opt to pay the demanded amount to avoid further litigation.
The GST demand order and penalty have significant implications for Alkem Laboratories. The company’s financial performance may be impacted, as it will need to provision for the payment of the tax demand and penalty. Additionally, the company’s reputation may be affected, as non-compliance with tax laws can damage a company’s credibility and trustworthiness.
The pharmaceutical industry is already facing significant challenges, including regulatory pressures, intense competition, and pricing pressures. The GST demand order and penalty will add to the company’s woes, making it even more challenging for Alkem Laboratories to navigate the complex regulatory landscape.
In conclusion, Alkem Laboratories has received a significant GST demand order with a penalty from the Additional Commissioner. The company is reviewing the order and will take necessary actions to address the issue. The demand order and penalty have significant implications for the company’s financial performance and reputation, and it remains to be seen how the company will navigate this challenge. The outcome of this case will be closely watched by the pharmaceutical industry, as it will set a precedent for other companies that may be facing similar GST-related issues.
Cipla Collaborates with ImmunoACT to Introduce CAR-T Cell Therapy for Blood Cancer Treatment in African Markets.
Cipla, a leading pharmaceutical company, has partnered with ImmunoACT, a biotech firm, to launch CAR-T cell therapy for the treatment of blood cancers in Africa. This collaboration aims to make this innovative and potentially life-saving treatment more accessible to patients in the region.
CAR-T cell therapy is a form of immunotherapy that involves extracting a patient’s T cells, genetically modifying them to recognize and attack cancer cells, and then reinfusing them back into the body. This treatment has shown remarkable success in treating certain types of blood cancers, including leukemia and lymphoma.
The partnership between Cipla and ImmunoACT will enable the development and commercialization of CAR-T cell therapy in Africa, where access to such treatments is currently limited. Cipla will leverage its extensive distribution network and manufacturing capabilities to support the launch of the therapy, while ImmunoACT will provide its expertise in CAR-T cell technology and clinical development.
The launch of CAR-T cell therapy in Africa is a significant milestone, as it has the potential to transform the treatment landscape for blood cancers in the region. Currently, many patients in Africa lack access to effective treatments for these diseases, resulting in poor outcomes and high mortality rates. The introduction of CAR-T cell therapy is expected to improve treatment options and outcomes for these patients.
The partnership also highlights the growing importance of collaboration between pharmaceutical companies, biotech firms, and healthcare providers in addressing the complex challenges of cancer treatment in Africa. By working together, these stakeholders can pool their resources, expertise, and knowledge to develop and deliver innovative treatments that can make a meaningful difference in the lives of patients.
In addition to improving treatment options, the launch of CAR-T cell therapy in Africa is also expected to drive awareness and education about blood cancers and the importance of early diagnosis and treatment. This, in turn, can help to reduce stigma and promote a better understanding of these diseases, ultimately leading to improved health outcomes for patients and their families.
Overall, the partnership between Cipla and ImmunoACT to launch CAR-T cell therapy in Africa represents a significant step forward in the fight against blood cancers in the region. By making this innovative treatment more accessible, the partners aim to improve treatment options, outcomes, and quality of life for patients, while also driving awareness and education about these diseases.
Delhi High Court Rejects Interim Injunction, Rules That Letters ‘A’ and ‘Z’ Are Not Exclusive Property.
The Delhi High Court has made a significant ruling in a trademark infringement case, stating that the use of letters “A” and “Z” cannot be monopolized by a single entity. The court refused an interim injunction sought by a company that claimed exclusive rights to the use of these letters in its brand name.
The plaintiff, AZ Tech, had filed a lawsuit against the defendant, Zee Entertainment, alleging that the latter’s use of the letters “A” and “Z” in its logo and branding was a violation of its trademark rights. AZ Tech claimed that it had been using the letters “A” and “Z” in its brand name since 2018 and had acquired a distinctive reputation in the market.
However, the court rejected AZ Tech’s argument, stating that the use of letters “A” and “Z” is not unique to the plaintiff and cannot be monopolized. The court observed that the letters “A” and “Z” are part of the alphabet and are commonly used in many words and brand names. The court also noted that the plaintiff’s trademark registration was not sufficient to establish exclusive rights over the letters “A” and “Z”.
The court’s decision is significant as it sets a precedent for future trademark cases involving the use of common letters and symbols. The ruling suggests that companies cannot claim exclusive rights over common elements of the alphabet, and that trademark protection is limited to distinctive and unique marks that are capable of distinguishing one company’s goods or services from those of another.
The court’s refusal of the interim injunction is also a victory for Zee Entertainment, which can continue to use its logo and branding without fear of infringement. The case highlights the importance of careful consideration and research in choosing a brand name and logo, to avoid potential trademark disputes. The ruling also underscores the need for companies to ensure that their trademarks are distinctive and unique, and not based on common elements that cannot be monopolized.
In conclusion, the Delhi High Court’s decision is a significant development in trademark law, emphasizing that common letters and symbols cannot be monopolized by a single entity. The ruling provides clarity and guidance for companies seeking to protect their brand names and logos, and highlights the importance of careful consideration and research in trademark selection.
Biocon Expects Robust Q3 Performance Fueled by Biosimilar Growth
Biocon, a leading biopharmaceutical company, is expected to have a strong third quarter in the fiscal year 2026 (Q3FY26). The company’s biosimilars segment is anticipated to drive this growth, with key products such as bStelara playing a significant role. Analysts predict substantial revenue growth, driven by the increasing adoption of biosimilars in emerging markets. The generics segment is also expected to contribute to the company’s growth, with new product launches in the pipeline.
This quarter’s results will be the first to reflect the consolidation of Biocon Biologics Limited (BBL), which is expected to have a positive impact on the company’s topline. Analysts estimate that the topline will surge by 18% due to the consolidation. The integration of BBL is expected to enhance Biocon’s biosimilars capabilities and increase its global footprint.
The biosimilars segment is expected to be a key driver of growth for Biocon, with products like bStelara, a biosimilar version of the monoclonal antibody Stelara, expected to contribute significantly to revenue. The company’s emerging market strategy is also expected to pay off, with increasing demand for biosimilars in these markets.
However, the generics segment is expected to face intense competition, which could impact the company’s growth prospects. Despite this, the segment is expected to show promise, with new product launches in the pipeline. The company’s focus on research and development is expected to yield new products and technologies, which will help drive growth in the long term.
Overall, Biocon is poised for a strong Q3FY26, driven by its biosimilars segment and emerging market traction. The consolidation of BBL is expected to have a positive impact on the company’s topline, and the generics segment is expected to show promise despite intense competition. With a strong pipeline of new products and a focus on research and development, Biocon is well-positioned for long-term growth and success. The company’s Q3FY26 results will be closely watched by investors and analysts, who will be looking for signs of continued growth and momentum.
Mankind Pharma launches digital smart classrooms initiative in Ghaziabad as part of its KindCare corporate social responsibility program.
Mankind Pharma, a leading Indian pharmaceutical company, has launched a digital smart classroom initiative in Ghaziabad as part of its corporate social responsibility (CSR) program, KindCare. The initiative aims to provide quality education to underprivileged students and bridge the digital divide in the region. The company has set up modern classrooms equipped with digital tools, such as smartboards, computers, and internet connectivity, to create an engaging and interactive learning experience.
The digital smart classrooms are designed to cater to the educational needs of students from marginalized communities, who often lack access to quality educational resources. The initiative is expected to benefit over 1,000 students in the first phase, with plans to expand to more schools and locations in the future. Mankind Pharma has partnered with local schools and NGOs to identify the most deserving students and provide them with access to these digital classrooms.
The KindCare program is a comprehensive CSR initiative launched by Mankind Pharma to address various social and environmental issues, including education, healthcare, and environmental sustainability. The program focuses on creating a positive impact on the community and promoting inclusive growth. Through the digital smart classroom initiative, Mankind Pharma aims to not only improve the quality of education but also prepare students for the digital age.
The company believes that education is a key driver of social mobility and economic growth, and that every child deserves access to quality education, regardless of their socio-economic background. By providing digital smart classrooms, Mankind Pharma is empowering students with the skills and knowledge required to succeed in an increasingly digital world. The initiative is also expected to have a positive impact on the local community, as it will help to create a more educated and skilled workforce, contributing to the region’s economic growth and development.
Mankind Pharma’s commitment to CSR is reflected in its efforts to make a positive impact on the community. The company’s digital smart classroom initiative is a testament to its dedication to creating a better future for underprivileged students and promoting inclusive growth. By leveraging technology and partnerships, Mankind Pharma is bridging the digital divide and empowering students to achieve their full potential. The initiative is a step towards creating a more equitable and sustainable future, where every child has access to quality education and opportunities to succeed.
Sun Pharma Sets Sights on $10 Billion Organon Takeover to Bolster US Presence
Sun Pharmaceutical Industries Ltd., India’s largest drug manufacturer, is considering a monumental acquisition of Organon, a US-based company specializing in women’s health and biosimilars. The potential deal, valued at $10 billion, is being led by the company’s founder, Dilip Shanghvi. If successful, this acquisition would be a significant milestone for Sun Pharma, enabling the company to expand its presence in the lucrative US market and accelerate its growth in the high-potential biosimilars sector.
The acquisition of Organon would provide Sun Pharma with a substantial boost in the US market, where the company has been seeking to increase its presence. Organon’s portfolio of women’s health products and biosimilars would complement Sun Pharma’s existing product line, enabling the company to offer a more comprehensive range of treatments to patients. Additionally, the deal would grant Sun Pharma access to Organon’s established distribution network and sales infrastructure in the US, facilitating the company’s ability to reach a broader customer base.
The biosimilars sector is a high-growth area, with increasing demand for affordable alternatives to branded biologic medications. By acquiring Organon, Sun Pharma would gain a significant foothold in this market, enabling the company to capitalize on the growing demand for biosimilars. The deal would also provide Sun Pharma with the opportunity to leverage Organon’s expertise in developing and commercializing biosimilars, further enhancing the company’s capabilities in this area.
The potential acquisition of Organon is a testament to Sun Pharma’s ambition to become a leading global pharmaceutical player. Under the leadership of Dilip Shanghvi, the company has been actively pursuing strategic acquisitions and partnerships to drive growth and expansion. The acquisition of Organon would be a major milestone in this journey, marking a significant step towards establishing Sun Pharma as a major player in the global pharmaceutical industry.
Overall, the potential acquisition of Organon by Sun Pharma is a significant development in the pharmaceutical industry, with far-reaching implications for the company’s growth and expansion. If successful, the deal would enable Sun Pharma to establish a strong presence in the US market, accelerate its growth in the biosimilars sector, and cement its position as a leading global pharmaceutical player.
Mankind Pharma launches cutting-edge digital classrooms, bolstering community-centric education through KindCare initiative, as reported by India Education Diary.
Mankind Pharma, a leading pharmaceutical company, has launched digital smart classrooms as part of its KindCare initiative, aiming to revolutionize community-first education in India. The inauguration of these state-of-the-art classrooms marks a significant milestone in the company’s efforts to bridge the educational gap and provide quality learning opportunities to underprivileged students.
The digital smart classrooms are equipped with modern technology, including interactive whiteboards, projectors, and high-speed internet connectivity. This infrastructure will enable students to access a wide range of educational resources, including e-learning materials, online tutorials, and virtual labs. The classrooms will also facilitate interactive learning experiences, allowing students to engage with teachers and peers in a more effective and immersive manner.
The KindCare initiative is a testament to Mankind Pharma’s commitment to giving back to the community. The company has been actively involved in various corporate social responsibility (CSR) activities, focusing on education, healthcare, and environmental sustainability. By introducing digital smart classrooms, Mankind Pharma aims to empower students from disadvantaged backgrounds, providing them with the skills and knowledge necessary to succeed in an increasingly competitive world.
The digital smart classrooms will cater to students from government schools and underprivileged communities, offering them access to quality education and resources that they may not have otherwise had. The initiative will also provide training and support to teachers, enabling them to effectively integrate technology into their teaching methods and create a more engaging learning environment.
Mankind Pharma’s KindCare initiative has received praise from educators, policymakers, and community leaders, who recognize the potential of digital smart classrooms to transform the education landscape in India. The company’s efforts are aligned with the government’s Digital India initiative, which aims to promote digital literacy and connectivity across the country.
By investing in digital smart classrooms, Mankind Pharma is not only contributing to the educational development of underprivileged students but also promoting social equity and inclusion. The company’s commitment to community-first education reflects its vision of creating a more just and equitable society, where every individual has access to quality education and opportunities for growth and development. As Mankind Pharma continues to expand its KindCare initiative, it is likely to have a profound impact on the lives of thousands of students, empowering them to achieve their full potential and create a brighter future for themselves and their communities.
Organs of Tiruppur road accident victim declared brain dead, donated to save multiple lives at Tiruchi hospital
A team of doctors at Apollo Speciality Hospitals in Tiruchi, India, successfully harvested organs from a 45-year-old brain-dead road accident victim, saving the lives of several patients in need of transplants. The woman, a resident of Kannivadi village in Tiruppur district, was involved in a road accident on January 14 and was initially treated at Apollo Hospitals in Karur before being transferred to the Tiruchi facility. Despite receiving intensive care, she was declared brain dead by the medical team.
The woman’s family made the selfless decision to donate her organs, which were then retrieved through a series of coordinated surgical procedures. The harvested organs included her heart, liver, kidneys, and lungs. The liver and kidneys were transplanted into patients at Apollo Speciality Hospitals in Tiruchi, while the remaining organs were allocated to patients on the waiting list in accordance with the guidelines of the Tamil Nadu Transplant Authority (TRANSTAN).
The organ donation was carried out with the full support of the woman’s family, who were praised for their generosity and selflessness. The hospital officials and local authorities also played a key role in facilitating the donation process. The mortal remains of the organ donor were laid to rest with full honors, with the final rites conducted in the presence of officials from the District Collector of Tiruppur, including the Dharapuram Revenue Divisional Officer and Tahsildar Officer, as well as senior police officials and representatives from Apollo Speciality Hospitals.
This heartwarming story highlights the importance of organ donation and the impact it can have on saving lives. The selfless act of the woman’s family has given a new lease of life to several patients in need of transplants, and serves as an inspiration to others to consider organ donation. The successful transplantation of the organs is a testament to the expertise and dedication of the medical team at Apollo Speciality Hospitals, and the coordination and support of the local authorities and TRANSTAN.
US Sales of Revlimid Decline, Offset by Strong Domestic Market Growth
The Indian pharmaceutical industry is bracing for a challenging earnings season in Q3, with expectations of muted margins due to the loss of patent exclusivity for the blockbuster blood cancer drug Revlimid in the US. Revlimid, which has generated over $100 billion in global sales, has been a significant revenue and margin driver for Indian drugmakers such as Dr Reddy’s Laboratories, Cipla, Zydus Lifesciences, and Sun Pharma. However, with the patent expiry in January 2026, these companies will have to offload their remaining quotas, leading to a decline in sales.
Analysts expect a sector-wide decline in earnings before interest, taxes, depreciation, and amortization (Ebitda) margins by 150 basis points year-on-year, with companies such as Dr Reddy’s, Cipla, and Zydus Lifesciences likely to be affected. The decline in Revlimid sales will be a significant contributor to this margin pressure, with prices expected to erode sharply as players look to offload remaining quotas. Additionally, other factors such as increased generic price competition in the US market, higher research and development (R&D) expenses, and rising selling, general, and administrative (SG&A) costs will also weigh on margins.
Despite these challenges, analysts remain optimistic about the sector’s overall revenue growth, with expectations of 8-11% growth driven by steady domestic growth and traction in other markets. Domestic sales are projected to outpace the broader Indian pharmaceutical market’s 10.1% growth, with the chronic segment showing particular strength. Companies such as Lupin, Sun Pharma, and Cipla are expected to see growth driven by their innovative medicines portfolios and recent launches.
The US market, however, is expected to be a challenge, with overall US sales projected to decline by 4% quarter-on-quarter due to lower Revlimid sales. Excluding Revlimid, US generic sales are forecast to grow by 2% quarter-on-quarter, driven by volume expansion in existing products and the benefits from recent launches. Overall, while the loss of Revlimid patent exclusivity will be a significant challenge for Indian pharmaceutical companies, their domestic growth and innovative medicines portfolios are expected to provide some resilience and drive overall revenue growth.
A 14-year-old patient suffering from sickle cell disease undergoes hip replacement surgery at Apollo Hospital.
A 14-year-old girl from Nigeria, Grace Natasha Mwanasa, has undergone a successful total hip replacement surgery at Indraprastha Apollo Hospital in New Delhi. The surgery, led by renowned orthopaedic surgeon Dr. Yash Gulati, is one of the youngest cases of total hip arthroplasty in a patient with sickle cell disease. Grace was diagnosed with sickle cell disease in early childhood and had experienced recurring sickle cell crises, requiring multiple hospitalizations, ICU care, and blood transfusions.
In December 2025, Grace was admitted to Apollo Hospital with severe left hip pain, inability to walk, limping, and disturbed sleep due to constant pain. Evaluation revealed advanced avascular necrosis and complete destruction of the left femoral head, a known complication of sickle cell disease. Due to her severe pain, complete loss of hip movement, and significant functional disability, the medical team decided to proceed with total hip replacement.
The surgery required extensive preoperative planning, including an exchange blood transfusion to reduce HbS levels, which is a key component of sickle cell disease. The medical team also took precautions during anesthesia and surgery, including hydration, prevention of hypothermia, and meticulous bleeding control. The surgery was a success, and Grace is expected to recover and regain her mobility.
Dr. Gulati and his team’s expertise and careful planning were crucial in the success of the surgery. The case highlights the importance of timely and proper medical intervention in managing sickle cell disease and its complications. The surgery has given Grace a new lease on life, and she is expected to make a full recovery. The case also underscores the capabilities of Indian healthcare, with Indraprastha Apollo Hospital emerging as a hub for complex surgeries and treatments. The successful surgery has brought hope to patients suffering from sickle cell disease and other complex medical conditions, and has demonstrated the potential for effective treatment and management of these conditions with proper medical care.
Apollo Hospitals Managing Director denies rumors of a family feud, citing the demerger as a deliberate business strategy.
Apollo Hospitals Enterprise is undergoing a significant restructuring process, spinning off its pharmacy and digital health businesses into a separate entity called Apollo HealthCo. Managing Director Suneeta Reddy has clarified that this decision is driven by a desire to enhance shareholder value and is not related to family differences or changes in promoter dynamics. The restructuring is intended to create focused value for shareholders by allowing each business to operate with tailored strategies and metrics.
The hospital business and pharmacy-digital business have fundamental differences, including their nature, return profile, growth drivers, and workforce. The hospital business is focused on healthcare services, while the pharmacy-digital business is retail-focused. The spin-off will allow each business to operate independently and make decisions that are best for their respective industries.
Apollo HealthCo is projected to achieve 20% growth and is expected to be listed by FY27. The hospitals business is expected to grow at 18% over the next three years. The company is pivoting towards preventive healthcare, driven by the increasing burden of non-communicable diseases in India. Key health challenges, such as genetic predisposition to cardiac problems, rising cancer incidences, and India’s large diabetic population, are driving this strategic shift.
The company has ambitious expansion plans, including continued focus on metro cities, building a significant presence in tier-I cities, and exploring opportunities in tier-II cities. Apollo is also open to asset-light models and acquisitions, recognizing the significant healthcare infrastructure gap in India.
The company is investing in technology, including telemedicine and AI-powered clinical intelligence, to scale high-quality clinical offerings to larger populations. Looking ahead, Apollo is preparing to serve diverse demographic cohorts, from the growing geriatric population to millennials and Gen Z, each requiring tailored healthcare approaches encompassing preventive health, lifestyle interventions, and nutraceuticals. The restructuring and expansion plans are intended to position Apollo for long-term success and growth in the healthcare industry.
The Delhi High Court has granted permission to Zydus to market a more affordable biosimilar version of the cancer medication Nivolumab, citing public interest.
The Delhi High Court has given a significant ruling in favor of Zydus, a pharmaceutical company, allowing it to sell a biosimilar version of the cancer drug Nivolumab at a lower price. Nivolumab, marketed under the brand name Opdivo by Bristol Myers Squibb, is a monoclonal antibody used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer. The court’s decision is expected to make the life-saving drug more accessible to patients in India.
Zydus had launched its biosimilar version of Nivolumab, called Itolizumab, in India, which is priced significantly lower than the original drug. However, Bristol Myers Squibb had approached the court, seeking an injunction to stop Zydus from selling the biosimilar, claiming that it infringed on their patent. The court, after hearing the arguments, ruled in favor of Zydus, stating that the company can continue to sell its biosimilar version of Nivolumab in the public interest.
The court’s decision is based on the fact that Nivolumab is a life-saving drug, and its high price makes it inaccessible to many patients in India. The court observed that the price of the original drug is exorbitant, and the biosimilar version launched by Zydus is priced at a significantly lower rate, making it more affordable for patients. The court also noted that Zydus has invested significant resources in developing the biosimilar and has obtained all necessary regulatory approvals.
The ruling is a significant win for patients in India, who will now have access to a more affordable version of the life-saving drug. The decision is also expected to have a positive impact on the Indian pharmaceutical industry, as it will encourage other companies to develop and launch biosimilars of expensive drugs, making them more accessible to patients.
The court’s decision is in line with the government’s efforts to make healthcare more affordable and accessible to all. The government has been promoting the use of biosimilars and generic drugs to reduce the cost of healthcare and make life-saving drugs more accessible to patients. The ruling is also expected to set a precedent for future cases, where pharmaceutical companies may approach the court to stop the sale of biosimilars, citing patent infringement. Overall, the court’s decision is a significant step towards making healthcare more affordable and accessible to all in India.
Piramal Pharma Enhances Its Global Sustainability Rating in Recent Corporate Assessment.
Piramal Pharma, a leading global pharmaceutical company, has achieved a significant improvement in its score on the Global Corporate Sustainability Assessment (CSA) conducted by S&P Global. The CSA is a widely recognized benchmark for assessing a company’s sustainability performance, evaluating factors such as environmental, social, and governance (ESG) practices.
In the latest assessment, Piramal Pharma’s score has increased by 13 points, reaching a total of 73 out of 100. This improvement reflects the company’s ongoing efforts to integrate sustainability into its business strategy and operations. The CSA assessment is based on a comprehensive evaluation of a company’s sustainability practices, including climate change, human rights, labor practices, and corporate governance.
The significant improvement in Piramal Pharma’s score can be attributed to its focused efforts on reducing its environmental footprint, enhancing its governance practices, and promoting social responsibility. Some of the key initiatives that contributed to this improvement include:
- Renewable energy: Piramal Pharma has increased its use of renewable energy sources, such as solar and wind power, to reduce its dependence on fossil fuels and lower its carbon emissions.
- Water conservation: The company has implemented water-saving measures and efficient wastewater management systems to minimize its water footprint.
- Waste reduction: Piramal Pharma has implemented a waste reduction program, which includes recycling and composting, to minimize waste disposal and reduce its environmental impact.
- Corporate governance: The company has strengthened its corporate governance practices, including board composition, executive compensation, and auditing practices.
- Social responsibility: Piramal Pharma has continued to invest in social responsibility initiatives, such as education, healthcare, and community development programs, to promote positive social impact.
The improved score on the Global Corporate Sustainability Assessment reflects Piramal Pharma’s commitment to sustainability and its efforts to create long-term value for its stakeholders. The company’s focus on sustainability is aligned with its mission to improve the quality of life for patients and communities worldwide. By integrating sustainability into its business strategy, Piramal Pharma aims to minimize its environmental footprint, promote social responsibility, and ensure long-term success.
Overall, Piramal Pharma’s achievement on the Global Corporate Sustainability Assessment demonstrates its dedication to sustainability and its commitment to creating a positive impact on the environment, society, and the economy. The company’s improved score serves as a testament to its efforts to balance business growth with social and environmental responsibility, making it a leader in the pharmaceutical industry.
Aurobindo Pharma Acquires Khandelwal Labs’ Non-Cancer Portfolio for ₹325 Crore.
Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for ₹325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the domestic market.
Khandelwal Laboratories is a Mumbai-based pharmaceutical company that operates in the areas of oncology and non-oncology. The company has a strong product portfolio in the non-oncology segment, with a focus on therapeutic areas such as neurology, cardiology, and gastroenterology. The non-oncology business of Khandelwal Laboratories includes a range of products, including tablets, capsules, and injectables.
The acquisition of Khandelwal Laboratories’ non-oncology business will add over 50 products to Aurobindo Pharma’s portfolio, including some well-established brands. The products will be marketed and distributed by Aurobindo Pharma’s existing sales team, which has a strong presence in the domestic market. The acquisition is expected to be completed in the next few months, subject to regulatory approvals.
Aurobindo Pharma has stated that the acquisition is in line with its strategy to expand its product portfolio and increase its presence in the domestic market. The company has been looking to strengthen its position in the Indian market, where it faces intense competition from other pharmaceutical companies. The acquisition of Khandelwal Laboratories’ non-oncology business is expected to help Aurobindo Pharma achieve this objective.
The acquisition is also expected to be beneficial for Khandelwal Laboratories, as it will allow the company to focus on its oncology business. Khandelwal Laboratories has a strong presence in the oncology segment, and the company is expected to use the proceeds from the sale to invest in its oncology business.
The deal is valued at ₹325 crore, which is a significant amount for a pharmaceutical company of Khandelwal Laboratories’ size. The acquisition price includes the cost of acquiring the non-oncology business, including the products, manufacturing facilities, and marketing rights. Aurobindo Pharma has stated that the acquisition will be funded through a combination of internal accruals and debt.
Overall, the acquisition of Khandelwal Laboratories’ non-oncology business by Aurobindo Pharma is a significant development in the Indian pharmaceutical industry. The deal is expected to strengthen Aurobindo Pharma’s position in the domestic market and provide the company with a strong portfolio of products in the non-oncology segment.
Lupin partners with Gan & Lee to bring fortnightly GLP-1 treatment to India through exclusive licensing deal.
Lupin Limited, a global pharmaceutical company, has entered into an exclusive agreement with Gan&Lee Pharmaceuticals of China to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. Bofanglutide is a fortnightly treatment for type 2 diabetes and weight management in overweight and obese adults, offering a reduced injection frequency compared to existing weekly GLP-1 therapies. Clinical data shows that the drug delivers comparable or better weight loss and glycaemic control outcomes, with a safety and tolerability profile consistent with the GLP-1 class.
The agreement strengthens Lupin’s metabolic health portfolio and marks its entry into the obesity treatment segment. India faces a significant burden of metabolic diseases, with an estimated 90 million adults living with diabetes and 50 million classified as obese. The convenience of a fortnightly dosing regimen may improve treatment adherence for patients requiring long-term therapy. Lupin’s Managing Director, Nilesh Gupta, commented that the agreement reflects the company’s commitment to expanding access to innovative therapies for chronic metabolic conditions.
The partnership also aligns with Gan&Lee Pharmaceuticals’ strategy to expand globally and bring its innovations to new markets. The company is a leading insulin manufacturer in China and has received regulatory approvals in multiple international markets. Lupin Limited, headquartered in Mumbai, operates in over 100 markets worldwide, with a strong presence in India and the United States. The company manufactures a range of products, including branded and generic formulations, complex generics, biotechnology products, and APIs, across 15 manufacturing sites and seven research centers globally.
The agreement is expected to benefit patients in India, where there is a growing need for effective treatments for metabolic diseases. With its strong presence in the Indian market, Lupin is well-positioned to commercialize Bofanglutide and make it accessible to patients who need it. The partnership between Lupin and Gan&Lee Pharmaceuticals is a significant development in the field of metabolic health and is expected to have a positive impact on the lives of millions of people in India and beyond.
Delhi High Court grants permission to Zydus to market Nivolumab biosimilar, a cancer treatment drug, in India.
The Delhi High Court has allowed Zydus Lifesciences to sell and market its biosimilar version of the anti-cancer drug nivolumab in India, despite a patent infringement suit filed by the innovator and patent holder, E.R. Squibb & Sons LLC. The court modified a previous order that had restrained the launch of Zydus’ biosimilar, citing public interest and the fact that the patent is set to expire on May 2, 2026. The bench of justices C. Hari Shankar and Om Prakash Shukla permitted continued sales of the biosimilar, directing Zydus to maintain detailed and audited records of its sales during this period so that Squibb can be compensated if it ultimately succeeds in the patent infringement suit.
Nivolumab is a life-saving cancer drug used to treat several types of cancer, including lung and head and neck cancer. The drug is expensive, with a vial costing between ₹21,500 to over ₹1,00,000, making affordability a concern. The dispute began when Squibb approached the Delhi High Court in 2024, alleging that Zydus was preparing to launch a biosimilar version of nivolumab before the expiry of its Indian patent. Squibb claimed that Zydus had developed a biosimilar, applied for regulatory approvals, and conducted clinical trials, indicating an imminent commercial launch during the patent term.
Zydus argued that its product did not infringe the patent and that it was developing a biosimilar in accordance with regulatory norms. The company also pointed to a pending post-grant opposition against Squibb’s patent filed by its group company. The court’s decision is a relief for Zydus and is expected to increase access to the life-saving drug for cancer patients in India. The court’s order also highlights the importance of balancing the rights of patent holders with the need to ensure access to affordable medicines, particularly in cases where the patent is nearing expiry.
The case is significant as it involves a biosimilar version of a critical cancer drug, and the court’s decision has implications for the pharmaceutical industry and patients in India. The court’s order is also a testament to the Indian judiciary’s commitment to ensuring that patent laws are balanced with the need to provide access to affordable medicines. The decision is expected to have a positive impact on the availability and affordability of cancer treatments in India, where the rate of cancer incidence is on the rise.
Alkem’s Renocia kit offers a cyclical nutritional supplement therapy designed to promote healthy hair growth.
Alkem Laboratories has launched a new product called Renocia cyclical therapy kit, a weekly nutritional supplementation regimen designed to support hair growth, strengthen hair follicles, and manage hair loss. The kit contains a set of vegetarian-sourced supplements, including vitamins, minerals, and amino acids, which are taken on specific days of the week. This structured protocol allows for better nutrient absorption and utilization.
According to Dr. Vikas Gupta, CEO of Alkem, nutritional supplementation plays a crucial role in hair health, but outcomes can vary depending on nutrient selection, absorption, and long-term adherence. The Renocia cyclical therapy kit offers a targeted approach that aligns with the body’s natural nutritional requirements throughout the week. By using only vegetarian-sourced ingredients, the company aims to make the product accessible to all sections of the Indian population.
The kit is available in a convenient wallet pack that contains supplements for four weeks, with clear instructions on which tablets to take on each day. The product is formulated separately for men and women to cater to their specific nutritional needs. Renocia cyclical therapy is a prescription product, and Alkem has a growing portfolio of products in the dermatology segment, including skin and hair care products.
The Renocia brand offers a range of hair care products, including hair revitalizing shampoo, conditioner, serum, and oral supplements. The launch of the cyclical therapy kit is a significant addition to the brand’s portfolio, providing a comprehensive solution for hair care. With its scientifically-designed regimen and vegetarian-sourced ingredients, the Renocia cyclical therapy kit is poised to make a positive impact on the hair care market in India.
Overall, the Renocia cyclical therapy kit is a innovative product that offers a structured approach to hair care, providing a convenient and effective solution for individuals looking to support hair growth and manage hair loss. With its focus on vegetarian-sourced ingredients and separate formulations for men and women, the product is likely to appeal to a wide range of consumers in India.
Mylan and Aurobindo Pharma must defend against allegations of colluding to fix prices for generic drugs.
A federal judge in Connecticut has rejected a request by Mylan Pharmaceuticals and Aurobindo Pharma USA to dismiss antitrust litigation against them. The judge ruled that a coalition of states has presented sufficient evidence to raise a genuine dispute about whether the companies conspired to fix drug prices. This decision allows the litigation to proceed against Mylan and Aurobindo, as well as 24 other pharmaceutical companies.
The antitrust litigation alleges that the pharmaceutical companies engaged in a conspiracy to fix prices, which is a violation of federal and state antitrust laws. The coalition of states, which is leading the litigation, claims that the companies’ alleged conspiracy has resulted in higher drug prices for consumers.
The judge’s decision is a significant setback for Mylan and Aurobindo, which had sought to have the litigation dismissed. The companies had argued that the states lacked sufficient evidence to support their claims, but the judge disagreed. The decision means that the litigation will continue, and the companies will be required to defend themselves against the allegations.
The litigation is part of a larger effort by states and federal authorities to crack down on alleged anticompetitive practices in the pharmaceutical industry. The industry has faced numerous lawsuits and investigations in recent years, and several companies have already settled allegations of price-fixing and other anticompetitive behaviors.
The judge’s decision is a victory for the coalition of states, which is seeking to hold the pharmaceutical companies accountable for their alleged actions. The litigation is likely to continue for several years, and the outcome is uncertain. However, the decision to allow the litigation to proceed is a significant step forward for the states and consumers who are seeking relief from high drug prices.
The case is being closely watched by the pharmaceutical industry and legal experts, who are interested in the potential implications of the litigation. A victory for the states could result in significant changes to the way pharmaceutical companies operate, and could lead to lower drug prices for consumers.
Biocon Biologics enhances its cancer treatment offerings with the introduction of three key biosimilar products.
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Limited, has announced plans to expand its oncology portfolio with the introduction of three new biosimilar candidates. The new additions include biosimilar versions of Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab, which are used to treat various types of cancer. With these new additions, Biocon Biologics will offer one of the broadest oncology biosimilar portfolios in the industry, addressing some of the world’s highest-revenue biologics that are expected to lose exclusivity over the next five years.
The company’s oncology portfolio represents a market opportunity exceeding $75 billion, accounting for nearly 35% of the global oncology pharmaceutical market. Biocon Limited has also announced plans to integrate Biocon Biologics as a wholly owned subsidiary, which is expected to simplify the corporate structure, enhance global commercial leverage, and strengthen Biocon’s leadership across diabetes, oncology, and immunology.
The integration, which is targeted to be completed by March 31, 2026, subject to regulatory approvals, will enable Biocon to offer biosimilar insulins alongside complex peptide generics, addressing the full continuum of diabetes care. Biocon Biologics’ CEO and Managing Director, Shreehas Tambe, commented that the integration will significantly enhance the company’s ability to deliver high-quality, affordable medicines at scale.
Biocon Biologics is a fully integrated global biosimilars company that serves over 6.3 million patients across 120 countries, providing high-quality biosimilars at affordable costs. The company has commercialized 10 biosimilars to date and has a pipeline of over 20 biosimilar assets spanning various therapeutic areas. Biocon Biologics is committed to advancing environmental, social, and governance priorities aligned with the United Nations Sustainable Development Goals.
The company’s expansion into the oncology market is expected to improve access to affordable cancer treatments worldwide. Biosimilars have been shown to be effective in reducing the cost of biologic treatments, making them more accessible to patients who may not have been able to afford them otherwise. With its expanded portfolio, Biocon Biologics is well-positioned to play a significant role in the global oncology market. The company’s commitment to delivering high-quality, affordable medicines is expected to have a positive impact on patients and healthcare systems worldwide.
The High Court has asked Novo Nordisk to respond to Natco’s request to cancel its patent.
The Delhi High Court has ordered Novo Nordisk, a Danish pharmaceutical company, to respond to a petition filed by Natco Pharma, a Hyderabad-based company, seeking to revoke the patent on the diabetes and anti-obesity drug semaglutide. The patent, which is set to expire in March, has been a subject of controversy, with Natco Pharma claiming that it lacks novelty and that Novo Nordisk is attempting to “evergreen” the patent to extend its exclusivity beyond the primary patent’s expiry.
Novo Nordisk has developed semaglutide and sells it under various brand names, including Wegovy, Rybelsus, and Ozempic, for the treatment of type-2 diabetes and weight loss. The company has regulatory approval to sell Ozempic in India. However, with the patent’s expiry looming, several generic companies, including Natco Pharma, are attempting to manufacture their own versions of the drug.
The Delhi High Court’s Justice Jyoti Singh has issued a notice to Novo Nordisk, directing the company to respond to Natco Pharma’s petition. The case has been listed for further hearing in February. The outcome of this case will have significant implications for the pharmaceutical industry, particularly in India, where there is a growing demand for affordable diabetes and obesity treatments.
Natco Pharma’s petition argues that Novo Nordisk’s patent on semaglutide is not novel and that the company is attempting to extend its exclusivity beyond the primary patent’s expiry. If the court rules in favor of Natco Pharma, it could pave the way for other generic companies to manufacture and sell their own versions of semaglutide, potentially increasing competition and reducing prices for the drug.
The case highlights the ongoing patent disputes in the pharmaceutical industry, particularly in India, where generic companies are increasingly challenging the patents of multinational pharmaceutical companies. The outcome of this case will be closely watched by the industry, as it could have significant implications for the availability and affordability of essential medicines in India and beyond.
Sun Pharmaceutical Industries suffers loss in trademark dispute as Bombay High Court rules EsiRaft and Raciraft do not bear deceptive similarities.
The Bombay High Court has ruled in favor of Eris Lifesciences, dismissing Sun Pharmaceutical’s claim that Eris’s medication “EsiRaft” infringed on Sun Pharma’s trademark for their medication “Raciraft”. The court found that the names “EsiRaft” and “Raciraft” are not deceptively similar, and therefore, Eris Lifesciences did not infringe on Sun Pharma’s trademark.
Sun Pharma had filed a lawsuit against Eris Lifesciences, alleging that the name “EsiRaft” was too similar to their own medication “Raciraft”, which could cause confusion among consumers. However, the Bombay High Court disagreed, stating that the names are distinct and not likely to cause confusion.
The court noted that the prefix “Esi” in EsiRaft is a well-known abbreviation for Eris Lifesciences, which is a well-established pharmaceutical company. In contrast, the prefix “Raci” in Raciraft is a unique identifier for Sun Pharma’s medication. The court also observed that the suffix “Raft” in both names is a common term used in the pharmaceutical industry to denote a type of medication.
The court’s decision is a significant win for Eris Lifesciences, as it allows the company to continue marketing and selling its medication “EsiRaft” without fear of trademark infringement. The ruling also sets a precedent for the pharmaceutical industry, establishing that minor similarities in medication names do not necessarily constitute trademark infringement.
The case highlights the importance of trademark law in the pharmaceutical industry, where companies invest heavily in developing and marketing their medications. The ruling demonstrates that courts will carefully consider the nuances of trademark law and the potential for consumer confusion when determining whether a trademark infringement has occurred.
In conclusion, the Bombay High Court’s decision in the case of Sun Pharma vs. Eris Lifesciences is a significant victory for Eris Lifesciences, allowing the company to continue marketing its medication “EsiRaft” without fear of trademark infringement. The ruling sets a precedent for the pharmaceutical industry and highlights the importance of careful consideration of trademark law in determining whether a trademark infringement has occurred.
PolyPeptide forms partnership with Lupin | Speciality Chemicals Magazine
PolyPeptide, a leading manufacturer of peptides, has formed a strategic alliance with Lupin Manufacturing Solutions. The partnership aims to establish a framework for long-term cooperation, focusing on integrated procurement and supply planning for select raw materials. This alliance will enable PolyPeptide to diversify its sourcing options for key materials, including metabolites, and create a more robust and flexible supply chain for peptide manufacturing.
The demand for peptides has been increasing, and this alliance will help PolyPeptide to better meet the growing needs of its customers. By collaborating with Lupin Manufacturing Solutions, PolyPeptide will be able to secure a stable supply of essential raw materials, reducing its dependence on a single supplier and minimizing potential risks.
This partnership is the second significant collaboration announced by PolyPeptide in recent times. The company has also signed a collaboration agreement with Lifecore Biomedical, a contract development and manufacturing organization (CDMO). The agreement combines PolyPeptide’s expertise in peptide manufacturing and development with Lifecore’s capabilities in formulation, fill-finish, and packaging.
The partnership with Lifecore Biomedical will provide US-based manufacturers of peptide drugs with an integrated, end-to-end solution. The collaboration will enable a seamless transition between drug substance and drug product, streamlining the manufacturing process and reducing costs. By offering a comprehensive solution, PolyPeptide and Lifecore Biomedical aim to become the preferred partners for companies developing peptide-based drugs.
The financial details of both alliances have not been disclosed. However, these partnerships demonstrate PolyPeptide’s commitment to enhancing its capabilities and expanding its reach in the peptide manufacturing market. By forming strategic alliances with other industry leaders, PolyPeptide is well-positioned to capitalize on the growing demand for peptides and maintain its position as a leading manufacturer in the industry.
The alliances with Lupin Manufacturing Solutions and Lifecore Biomedical will enable PolyPeptide to improve its supply chain, reduce costs, and offer a more comprehensive range of services to its customers. As the demand for peptides continues to increase, PolyPeptide’s strategic partnerships will play a crucial role in driving its growth and success in the market.
National Pharmaceutical Pricing Authority Caps Retail Price of Sun Pharma’s Gemcitabine Injections
The National Pharmaceutical Pricing Authority (NPPA) has set the retail price for Sun Pharma’s Gemcitabine injections. Gemcitabine is a chemotherapy medication used to treat various types of cancer, including pancreatic, breast, ovarian, and non-small cell lung cancer. The NPPA, which is responsible for regulating the prices of pharmaceutical products in India, has fixed the retail price of Sun Pharma’s Gemcitabine injections to ensure that the medication is affordable for patients.
The price fixation is a significant move, as it will help to make the life-saving medication more accessible to cancer patients in India. Gemcitabine is a critical component of cancer treatment, and its high cost has been a significant burden on patients and their families. The NPPA’s decision is expected to provide relief to patients who are struggling to afford the medication.
The retail price of Sun Pharma’s Gemcitabine injections has been fixed at a level that is significantly lower than the existing market price. This will result in significant savings for patients who are undergoing cancer treatment. The price reduction is expected to benefit thousands of patients who are dependent on Gemcitabine for their treatment.
The NPPA’s decision is in line with the government’s efforts to make healthcare more affordable and accessible to all. The authority has been working to regulate the prices of pharmaceutical products, including cancer medications, to ensure that they are affordable for patients. The price fixation of Gemcitabine is a significant step in this direction and is expected to have a positive impact on the healthcare sector.
The move is also expected to promote competition in the market, as other pharmaceutical companies may be forced to reduce their prices to remain competitive. This will ultimately benefit patients, who will have access to affordable and high-quality medication. The NPPA’s decision is a significant development in the pharmaceutical sector and is expected to have a positive impact on the healthcare industry as a whole.
Overall, the NPPA’s decision to fix the retail price of Sun Pharma’s Gemcitabine injections is a welcome move that will benefit cancer patients in India. The price reduction will make the medication more accessible and affordable, and will help to reduce the financial burden on patients and their families. The move is in line with the government’s efforts to make healthcare more affordable and accessible, and is expected to have a positive impact on the healthcare sector.
GCC will operate dialysis centers in Kolathur and Kondithope.
The Greater Chennai Corporation (GCC) will oversee and maintain two dialysis centers being constructed by the Chennai Metropolitan Development Authority (CMDA) in Kolathur and Kondithope. The centers will provide blood purification services, and the GCC has proposed covering the beneficiaries under the Chief Minister’s Comprehensive Health Insurance Scheme (CMCHIS). Until the scheme is formally approved, the GCC will bear the dialysis treatment costs, which will be operated by Apollo Hospitals.
The Kolathur center, located in the Thiru-Vi-Ka Nagar zone, will be a multi-story facility offering integrated services. The center will have an artificial limb center on the first floor, a physical training center on the second floor, a blood purification unit for dialysis procedures on the third floor, and patient amenities on the fourth floor. Similarly, the Kondithope facility, located in the Royapuram zone, will function as a comprehensive rehabilitation center with similar facilities.
The decision to establish these centers was made in a meeting chaired by CMDA Minister PK Sekarbabu in September. The meeting decided that while the CMDA would establish the facilities, the GCC would handle their operation and maintenance. The GCC’s joint commissioner (Health) and the North Chennai regional deputy commissioner were also present at the meeting.
The construction of these dialysis centers aims to provide accessible and affordable healthcare services to the residents of Chennai. The GCC’s decision to bear the treatment costs until the CMCHIS is approved ensures that the beneficiaries can receive the necessary treatment without any delays. The comprehensive rehabilitation centers will also provide a range of services, including artificial limb fitting, physical training, and patient amenities, making them a one-stop destination for patients requiring dialysis and rehabilitation services. Overall, the establishment of these centers is expected to improve the healthcare infrastructure in Chennai and provide better services to the residents.
Aurobindo Pharma Pushes Back Deadline to Purchase 26% Stake in Swarnaakshu Solar
Aurobindo Pharma has extended the timeline to acquire a 26% stake in Swarnaakshu Solar, a solar power company. The acquisition is part of Aurobindo Pharma’s strategy to diversify its business and invest in renewable energy.
The company had initially planned to complete the acquisition by a certain deadline, but it has now been extended due to various reasons. The extension of the timeline is expected to give Aurobindo Pharma more time to complete the necessary formalities and regulatory approvals.
Aurobindo Pharma is one of the leading pharmaceutical companies in India, and its decision to invest in Swarnaakshu Solar marks a significant departure from its core business. The company has been looking to diversify its portfolio and reduce its dependence on the pharmaceutical sector.
Swarnaakshu Solar is a solar power company that specializes in the development and operation of solar power plants. The company has a strong presence in the Indian renewable energy market and has developed several solar power projects across the country.
The acquisition of a 26% stake in Swarnaakshu Solar is expected to give Aurobindo Pharma a significant foothold in the renewable energy sector. The company plans to use the investment to expand its presence in the solar power market and to reduce its carbon footprint.
The extension of the timeline to acquire a stake in Swarnaakshu Solar is not expected to have a significant impact on Aurobindo Pharma’s financial performance in the short term. However, the investment is expected to provide long-term benefits to the company and help it to achieve its sustainability goals.
Aurobindo Pharma’s decision to invest in Swarnaakshu Solar is part of a larger trend of pharmaceutical companies diversifying their business and investing in renewable energy. The investment is expected to help the company to reduce its dependence on fossil fuels and to achieve its sustainability goals.
Overall, the extension of the timeline to acquire a stake in Swarnaakshu Solar is a positive development for Aurobindo Pharma and marks a significant step forward in the company’s strategy to diversify its business and invest in renewable energy. The investment is expected to provide long-term benefits to the company and help it to achieve its sustainability goals.
Delhi High Court bars Dr Reddy’s from producing VENUSIA sunscreens bearing the SUN logo.
The Delhi High Court has issued an interim order restraining Dr. Reddy’s Laboratories from manufacturing and selling its VENUSIA sunscreens with a label that includes the word “SUN”. The court’s decision comes in response to a lawsuit filed by Glenmark Pharmaceuticals, which claims that Dr. Reddy’s is infringing on its trademark rights.
Glenmark Pharmaceuticals had launched its own sunscreen product, SUNSTAR, in 2018, and had obtained a trademark registration for the mark “SUN” in relation to sunscreen products. The company claims that Dr. Reddy’s use of the word “SUN” on its VENUSIA sunscreens is likely to cause confusion among consumers and dilute the distinctiveness of Glenmark’s trademark.
The Delhi High Court has agreed with Glenmark’s arguments, observing that Dr. Reddy’s use of the word “SUN” on its products is likely to cause confusion among consumers, who may mistakenly believe that the VENUSIA sunscreens are connected to Glenmark’s SUNSTAR product. The court has therefore restrained Dr. Reddy’s from using the word “SUN” on its VENUSIA sunscreens, pending the outcome of the lawsuit.
The court’s order is a significant setback for Dr. Reddy’s, which had launched its VENUSIA sunscreens with the SUN label in an attempt to capitalize on the popularity of sunscreens in the Indian market. The company will now have to rebrand its products and remove the SUN label, which could result in significant losses and damage to its reputation.
The lawsuit highlights the importance of trademark protection in the pharmaceutical industry, where companies invest heavily in building their brands and trademarks. The Delhi High Court’s decision demonstrates that courts will take a strict view of trademark infringement, particularly in cases where there is a likelihood of confusion among consumers.
The case will now proceed to trial, where Glenmark will have to prove that Dr. Reddy’s use of the word “SUN” on its VENUSIA sunscreens constitutes trademark infringement. If the court ultimately rules in favor of Glenmark, Dr. Reddy’s could face significant damages and penalties for its alleged infringement. The case is being closely watched by the pharmaceutical industry, which is keen to see how the courts will interpret trademark laws in cases of alleged infringement.
Tragedy strikes in Bengaluru as 26-year-old Biocon staff member takes fatal leap from 5th floor of office building.
A 26-year-old employee of Biocon, a biopharmaceutical company, jumped to his death from the 5th floor of the company’s office building in Bengaluru, India. The incident occurred on a recent day, and the police are currently investigating the circumstances surrounding the death.
According to reports, the employee, whose identity has not been disclosed, was working in the research and development department of Biocon. He was a resident of Bengaluru and had been working with the company for several years. The police have stated that they are reviewing CCTV footage and speaking with colleagues and family members to determine the cause of the incident.
The incident has sent shockwaves through the company, with many colleagues and friends expressing their condolences on social media. Biocon has released a statement expressing its sadness and shock at the incident, and has offered support to the employee’s family.
The police have ruled out any foul play in the incident, and are treating it as a case of suicide. However, they are still investigating the circumstances that led to the employee’s death, including any potential work-related stress or personal issues.
This incident highlights the growing concern of mental health and stress in the corporate world, particularly in the tech and biotech industries. Many employees in these industries face high levels of stress and pressure to perform, which can take a toll on their mental health. Companies are increasingly recognizing the importance of providing support and resources to employees to manage stress and promote mental well-being.
Biocon has a reputation for being a supportive and employee-friendly company, with a range of initiatives and programs in place to promote employee well-being. However, this incident highlights the need for companies to do more to support employees who may be struggling with mental health issues.
The incident is also a reminder of the importance of seeking help and support when struggling with mental health issues. If you or someone you know is struggling with mental health issues, there are resources available to help. The National Institute of Mental Health and Neuro Sciences (NIMHANS) has a 24-hour helpline that provides support and counseling services. Additionally, many companies have employee assistance programs (EAPs) that provide confidential counseling and support services to employees.
India’s pharmaceutical sector faces a pivotal year of transformation: Adapting to change and embracing a shifting worldwide landscape | Hindustan Times
The Indian pharmaceutical industry has faced significant challenges in recent years, but 2022 has been a defining year for the sector. The industry has had to navigate disruptions caused by the COVID-19 pandemic, regulatory changes, and global trade tensions. Despite these challenges, Indian pharma has shown resilience and adaptability, and is now preparing for a new global order.
One of the major disruptions faced by the industry has been the pandemic, which has led to supply chain disruptions, lockdowns, and changes in demand patterns. However, Indian pharma companies have responded by investing in digital transformation, diversifying their product portfolios, and expanding their global footprint. The industry has also seen a significant increase in investments in research and development, with a focus on developing new and innovative products.
Regulatory changes have also been a major challenge for the industry. The Indian government has introduced several policies aimed at promoting the domestic pharmaceutical industry, including the Production Linked Incentive (PLI) scheme, which provides incentives to companies that invest in domestic manufacturing. The government has also introduced new regulations aimed at improving the quality of pharmaceutical products and reducing the risk of counterfeit medicines.
Despite these challenges, the Indian pharmaceutical industry has continued to grow, with exports increasing by over 20% in the past year. The industry has also seen a significant increase in foreign investments, with several global companies investing in Indian pharma companies. The industry is also expected to benefit from the government’s efforts to promote the development of a domestic pharmaceutical industry, including the establishment of pharmaceutical parks and clusters.
As the industry prepares for a new global order, it is likely to face new challenges and opportunities. The COVID-19 pandemic has accelerated the trend towards digitalization and online healthcare, and Indian pharma companies will need to invest in digital technologies to remain competitive. The industry will also need to navigate the changing global trade landscape, including the impact of Brexit and the US-China trade war.
Overall, 2022 has been a defining year for the Indian pharmaceutical industry, with the sector navigating significant disruptions and preparing for a new global order. The industry has shown resilience and adaptability, and is well-positioned to take advantage of new opportunities and challenges in the coming years. With the government’s support and the industry’s own efforts, Indian pharma is likely to continue to grow and thrive, and play an increasingly important role in the global pharmaceutical industry.
Indian pharma companies are working to develop new and innovative products, including vaccines, biologics, and gene therapies. The industry is also investing in emerging technologies such as artificial intelligence, blockchain, and the Internet of Things (IoT) to improve the quality and efficiency of its operations. As the industry looks to the future, it is clear that Indian pharma will play an increasingly important role in the global pharmaceutical industry, and will continue to be a major driver of economic growth and innovation in India.
Bombay High Court Denies Sun Pharma’s Request for Temporary Restraining Order Against Competitor EsiRaft, Allowing it to Continue Challenging RACIRAFT
The Bombay High Court has refused to grant an interim injunction to Sun Pharmaceutical Industries Limited, allowing Meghmani Lifesciences Limited to continue using the trademark “EsiRaft” for its pharmaceutical product. The court found that the mark is not deceptively similar to Sun Pharma’s “RACIRAFT” and that there is no likelihood of confusion between the two marks.
Sun Pharma had filed a trademark infringement and passing off suit against Meghmani Lifesciences, claiming that the use of “EsiRaft” infringed on its goodwill and was likely to cause confusion among consumers. However, the court held that the marks are visually and phonetically dissimilar and that the element “RAFT” is descriptive of the product’s characteristics and cannot be used to establish deceptive similarity.
The court also noted that the prefixes “RACI” and “ESI” are distinct and that Meghmani Lifesciences’ adoption of the mark was bona fide. The company had explained that “ESI” referred to “Enhanced System Improvement” and “Esophageal Symptom Index”. The court observed that the use of two-color combinations on the packaging was common in the trade and was insufficient to establish infringement.
The court applied the principles of trademark law, including the anti-dissection rule, the viewpoint of an average consumer with imperfect recollection, and the likelihood of confusion. It found that the competing marks are prima facie visually and phonetically dissimilar and will not create any confusion in the minds of consumers.
In dismissing Sun Pharma’s interim injunction plea, the court held that the company had failed to make out a prima facie case of trademark infringement or passing off. The court also vacated an earlier ex-parte ad-interim injunction that had restrained Meghmani Lifesciences from using the disputed mark. The decision allows Meghmani Lifesciences to continue using the “EsiRaft” mark for its product, which is used to treat heartburn and indigestion.
The case highlights the importance of careful consideration of trademark similarity and the need for companies to establish a strong case of infringement or passing off in order to obtain an interim injunction. The court’s decision is significant, as it allows Meghmani Lifesciences to continue marketing its product without interruption, while also protecting the rights of Sun Pharma to pursue its claims in the main suit.
The court’s observation that the get-up of the marks itself is different and the overall visual appearance of the rival products is dissimilar, is crucial in determining the likelihood of confusion. The decision also emphasizes the need for companies to ensure that their trademarks are distinctive and do not infringe on the rights of other companies.
In conclusion, the Bombay High Court’s decision in this case provides guidance on the principles of trademark law and the factors that are considered in determining the likelihood of confusion between two marks. The decision is a significant one, as it allows Meghmani Lifesciences to continue using the “EsiRaft” mark, while also protecting the rights of Sun Pharma to pursue its claims in the main suit.
Sun Pharma Wins Reprieve as CESTAT Sends Back Rs. 3.90 Crore Excise Demand for Re-Assessment Over EOU DTA Sales and Deemed Exports – Juris Hour
The Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) has remanded a Rs. 3.90 crore excise demand against Sun Pharmaceutical Industries Ltd. regarding sales from an Export Oriented Unit (EOU) to a Domestic Tariff Area (DTA). The tribunal has directed the authorities to recalculate the deemed exports and the corresponding excise duty liability.
The dispute arose from the company’s sales from its EOU to its DTA unit, which were treated as deemed exports under the Export and Import Policy. The excise authorities demanded duty on these sales, claiming that they were not genuine exports. Sun Pharma argued that the sales were eligible for exemption under the exemption notification, as they were deemed exports.
The CESTAT observed that the excise authorities had not properly verified the deemed export benefits claimed by the company. The tribunal noted that the authorities had not considered the export proceeds realized by the company and had not verified the consumption of the goods in the DTA.
The CESTAT held that the excise authorities’ demand was not sustainable and remanded the matter to the original authority to recalculate the deemed exports and the corresponding excise duty liability. The tribunal directed the authorities to consider the export proceeds realized by the company and to verify the consumption of the goods in the DTA.
The CESTAT’s order is significant, as it clarifies the treatment of sales from an EOU to a DTA under the excise law. The order also highlights the importance of proper verification and calculation of deemed export benefits. The remand order will allow the authorities to re-examine the company’s claims and calculate the correct excise duty liability.
The case emphasizes the need for exporters to maintain accurate records and documentation to support their claims for deemed export benefits. It also underscores the importance of proper verification and calculation by the excise authorities to ensure that the correct excise duty liability is determined. The CESTAT’s order will provide guidance to other exporters and excise authorities in similar cases, ensuring consistency and clarity in the application of the excise law.
Experts from Apollo, Aster CMI, and Fortis warn that snoring may be a warning sign of underlying heart issues, citing five key reasons.
Persistent, loud snoring is often dismissed as a harmless nighttime habit, but it can be a warning sign of obstructive sleep apnea (OSA), a condition that puts the heart under constant stress. According to leading medical experts, OSA can lead to high blood pressure, irregular heart rhythms, and eventually, heart failure. Dr. Varun Bansal, a senior consultant at Indraprastha Apollo Hospitals, states that snoring is frequently trivialized, yet its impact on the body is profound, and is strongly linked with changes in the way the heart and blood vessels work.
Experts have identified five critical ways that chronic snoring and sleep apnea damage the cardiovascular system:
- Oxygen deprivation and heart stress: When snoring transitions into sleep apnea, the airway becomes blocked, causing breathing to stop for seconds or even a minute, leading to a state of emergency and triggering stress systems that spike the heart rate.
- The link to ‘stubborn’ high blood pressure: Blood pressure stays elevated or surges during apnea episodes, making the heart muscle stiff and less functional over time.
- Dangerous heart rhythm disturbances: The repeated ‘stop-start’ nature of breathing during sleep stimulates stress hormones like adrenaline, increasing the risk of Atrial Fibrillation (AFib) and other irregular heartbeats.
- Inflammation and vascular damage: Repeated breathing pauses trigger systemic inflammation, damaging the lining of the blood vessels and speeding up plaque buildup (atherosclerosis), which can lead to heart attacks and weakened heart function.
- The ‘vicious cycle’ of metabolic stress: Snoring is tightly correlated with abdominal obesity and diabetes, and sleep disruption interferes with hunger hormones, leading to weight gain, which in turn worsens snoring.
The warning signs of sleep apnea that shouldn’t be ignored include daytime fatigue, gasping for air or choking sounds during sleep, morning headaches, and high blood pressure that doesn’t respond well to medication. While occasional snoring due to a cold or alcohol use is generally not dangerous, doctors urge a medical evaluation if snoring is accompanied by these symptoms.
The good news is that heart damage caused by sleep apnea is often preventable and sometimes reversible if caught early. Treatments like CPAP devices, weight management, and lifestyle changes can stabilize heart rhythms and lower blood pressure. If you or a loved one are chronic snorers, a sleep study could be the first step in protecting your heart’s future. It’s essential to seek medical advice if you’re concerned about snoring or sleep apnea, as early detection and treatment can make a significant difference in preventing long-term heart damage.
Glenmark Pharmaceuticals USA has introduced a multiple-dose vial of epinephrine injection.
Glenmark Pharmaceuticals Inc, USA, has launched Epinephrine Injection USP, a bioequivalent and therapeutically equivalent product to the reference listed drug manufactured by BPI Labs, LLC. The product is available in a 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial and is intended for the U.S. market. According to IQVIA sales data, the Epinephrine Injection market had annual sales of approximately USD 67.6 million for the 12 months ending October 2025. This launch expands Glenmark’s institutional product portfolio and reinforces its commitment to providing high-quality, affordable treatment options.
Glenmark Pharmaceuticals Limited is a prominent Indian multinational pharmaceutical company that has been in operation since 1977. The company has grown from its origins in generic medicines and active pharmaceutical ingredients (APIs) to become a research-led global healthcare organization with a presence in over 80 countries. Glenmark’s core therapeutic expertise includes respiratory, dermatology, oncology, cardiovascular, and anti-infective treatments, with multiple R&D centres and manufacturing facilities across India and internationally.
In recent years, Glenmark has diversified into innovative drug development and biosimilars, while maintaining a strong portfolio of branded generics in high-growth markets. The company has also entered strategic collaborations and licensing deals to advance novel therapies, particularly in oncology. Despite facing quality control challenges in some manufacturing facilities, Glenmark continues to pursue a transformation towards a more innovation-centric business model aimed at increasing its branded portfolio and long-term global competitiveness.
The launch of Epinephrine Injection USP is part of Glenmark’s strategy to strengthen its institutional channel presence and improve access to essential medicines. According to Marc Kikuchi, President and Business Head for North America at Glenmark, the launch supports the company’s commitment to providing high-quality, affordable treatment options. With its robust revenue growth and expanding demand in key markets such as North America and Europe, Glenmark is well-positioned to continue its growth and expansion in the global pharmaceutical market.
The US FDA has issued a recall for an antifungal shampoo manufactured by Sun Pharma.
The US Food and Drug Administration (USFDA) has announced a recall of over 17,000 units of antifungal shampoo, Ciclopirox Shampoo, due to manufacturing issues. The recall was initiated by Taro Pharmaceutical Industries, the US arm of Sun Pharma, on December 9. The shampoo is used to treat seborrheic dermatitis, a condition that causes dry, flaky, and itchy skin. The recall was classified as a Class II recall, which means that the product’s use may lead to temporary or medically reversible health consequences, but the likelihood of serious adverse health outcomes is minimal.
The recall was due to “failed impurity/degradation specifications,” according to the USFDA. Taro Pharmaceutical Industries is a private company and a wholly-owned subsidiary of Sun Pharma, which acquired the Israel-based company in a deal valued at $347.73 million last year. Sun Pharma has been the majority shareholder of Taro since 2010. Taro primarily focuses on dermatology and produces a wide range of prescription and over-the-counter products.
The recall is a setback for Sun Pharma, which is a leading exporter to the US market. In the second quarter of FY26, the company reported revenue of Rs 14,478 crore, with a net profit of Rs 3,118 crore, a 2.56% increase year-on-year. However, formulation sales in the US declined 4.1% to $496 million. The recall highlights the importance of quality control and regulatory compliance in the pharmaceutical industry.
The USFDA’s Enforcement Report noted that the recall was nationwide and affected 17,664 units of the Ciclopirox Shampoo. The company has taken prompt action to address the issue, and the recall is expected to minimize any potential harm to consumers. The incident serves as a reminder of the need for pharmaceutical companies to maintain high standards of quality and manufacturing practices to ensure the safety and efficacy of their products.
Zydus Lifesciences Partners with Myriad Genetics to Introduce Cutting-Edge Cancer Diagnostic Solutions in India.
Zydus Lifesciences Limited, a global life sciences company, has partnered with US-based Myriad Genetics to introduce advanced cancer-risk assessment and prognostic diagnostic tests in India. The exclusive agreement allows Zydus to offer Myriad’s MyRisk Hereditary Cancer Test, MyChoice HRD Plus Test, and Prolaris Prostate Cancer Prognostic Test to patients, clinicians, and healthcare institutions across the country. These tests provide actionable insights into hereditary risk, disease progression, and treatment planning, enabling personalized and evidence-based cancer care.
The MyRisk test helps individuals and families understand genetic cancer risk, enabling informed lifestyle choices and monitoring. The Prolaris and MyChoice HRD Plus tests provide clinically validated insights that guide treatment selection and predict disease progression for patients with prostate and ovarian cancers. With cancer incidence rising worldwide, early identification of inherited risk plays a critical role in prevention and proactive health management.
Dr. Sharvil P Patel, Managing Director of Zydus Lifesciences, stated that the partnership represents a significant step toward improving access to precision diagnostics in India. The tests offer clinicians valuable tools to personalize treatment strategies, assess disease aggressiveness, and streamline clinical decision-making, ultimately helping patients achieve better outcomes. The collaboration reflects Zydus’ continued focus on patient-centric care and precision oncology.
Brian Donnelly, Chief Commercial Officer of Myriad Genetics, emphasized that the collaboration with Zydus will help expand the reach of precision oncology solutions across India. Myriad’s tests are designed to equip clinicians with clear, actionable insights into genetic risk and tumor biology, supporting personalized care and informed treatment decisions. The Prolaris test, in particular, offers a clinically proven method to assess disease aggressiveness and guide treatment choices for prostate cancer patients.
Zydus Lifesciences Limited is an innovation-led life sciences company with a strong presence in pharmaceuticals, consumer wellness, and MedTech. The company operates globally, employing over 29,000 people, including a robust R&D workforce dedicated to advancing healthcare solutions. Myriad Genetics is a global leader in molecular diagnostics and precision medicine, developing tests that assess disease risk, predict progression, and guide treatment decisions across multiple medical specialties. The partnership aims to support earlier and more accurate cancer risk assessment, enabling patients to make informed decisions with greater confidence.
Zydus Lifesciences Partners to Introduce Diagnostic Tests for Cancer Risk Evaluation in Indian Market
Zydus Lifesciences Limited is a global life sciences company based in India that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare therapies. The company operates in the business of integrated pharmaceutical operations, offering a diverse product portfolio that includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary products, as well as health and wellness products.
The company’s product portfolio is categorized into several segments, including India formulations, generics, and Zydus biologics. Some of its notable products include Lipaglyn and Bilypsa (Saroglitazar), which are used to treat various health conditions. Additionally, the company offers a range of biosimilars, such as Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar), and Bryxta (Bevacizumab biosimilar), which are used to treat various diseases, including cancer and autoimmune disorders.
Zydus biologics, a key segment of the company, covers a wide range of therapeutic areas, including oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, among others. The company’s products are designed to provide effective treatment options for patients with various health conditions, and its biosimilars are developed to be more affordable and accessible alternatives to traditional biologic therapies.
With a global presence, Zydus Lifesciences Limited markets its products in several key regions, including the United States, India, Europe, and emerging markets. The company’s global reach and diverse product portfolio have established it as a significant player in the global life sciences industry. Through its commitment to innovation and quality, Zydus Lifesciences Limited aims to provide effective and affordable healthcare solutions to patients around the world. Overall, the company’s broad range of products and global presence have positioned it for continued growth and success in the life sciences industry.
Glenmark secures $1 billion deal for multi-regional rights to Hansoh Pharma’s cancer treatment medication.
Glenmark Specialty S.A., a subsidiary of India-based Glenmark Pharmaceuticals, has entered into a licensing agreement with China’s Jiangsu Hansoh Pharmaceutical Group Co. for the oncology drug Aumolertinib. The agreement grants Glenmark exclusive rights to develop and commercialize Aumolertinib in several high-potential markets, including the Middle East, Africa, Southeast and South Asia, Australia, New Zealand, Russia, and the Caribbean. In return, Hansoh Pharma will receive an upfront payment of tens of millions of dollars, followed by potential milestone payments of over $1 billion, as well as tiered royalties on net sales.
Aumolertinib is a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) used to treat non-small cell lung cancer (NSCLC). The drug has already received marketing authorization in the UK and China, and has been approved for four indications in China. It is also marketed in the UK and Europe under the brand names Ameile and Aumseqa. The partnership strengthens Glenmark’s oncology strategy across these regions, providing access to a promising new treatment for patients with NSCLC.
The agreement marks a significant milestone for Hansoh Pharma, as Aumolertinib is the company’s first innovative drug to be approved in an overseas market. It is also the first China-developed EGFR-TKI to be launched internationally. The deal demonstrates the growing importance of partnerships between pharmaceutical companies to bring new treatments to market and expand their global reach. With the potential for milestone payments of over $1 billion, the agreement also highlights the significant value of innovative oncology treatments and the growing demand for effective therapies in this field. Overall, the partnership between Glenmark and Hansoh Pharma has the potential to bring a new and effective treatment option to patients with NSCLC in several regions, and marks an important step forward in the development of innovative oncology therapies.
According to Apollo doctors, adopting this one simple habit can significantly lower the risk of premature heart attacks and increase lifespan.
Dr. Sudhir Kumar, a neurologist from Apollo Hospitals in Hyderabad, recently shared his personal experience of completing a half marathon after a 14-hour fasting window. Despite the distance, he maintained a comfortable pace and low heart rate, demonstrating the deep health benefits of endurance running. His run showcased efficient fuel usage, with his body burning fat for energy instead of relying on stored carbohydrates. This level of metabolic adaptability is typically developed through years of regular aerobic conditioning and reflects a resilient metabolism.
The run also highlighted the benefits of a strong and economical heart, with Dr. Kumar’s heart rate remaining low and steady throughout the run. This suggests improved stroke volume, balanced nervous system control, and reduced stress on the heart, all of which are closely linked to slower biological aging and better cardiovascular outcomes. Additionally, exercising in a fasted state within moderate intensity zones helped his muscles absorb glucose more effectively, improving insulin responsiveness and reducing the risk of metabolic disorders.
Dr. Kumar’s approach to running also emphasized the importance of avoiding excessive stress hormone release and oxidative damage. By limiting high-intensity exertion, he supported quicker recovery, lowered chronic inflammation, and contributed to long-term heart and vascular health. The absence of energy crashes, stable pacing, and minimal heart rate drift during his run indicate a form of fitness that can be repeated consistently, building stamina that supports health for decades.
The core takeaway from Dr. Kumar’s experience is that extreme speeds, fancy supplements, or sugary fuels are not necessary to gain meaningful health benefits. Instead, a solid aerobic foundation, regular practice, and patience are far more powerful than shortcuts. By incorporating endurance running into one’s lifestyle, individuals can support long-term wellbeing and reduce the risk of chronic diseases. As a reliable and trusted news source, it is essential to emphasize the importance of sustainable and consistent exercise habits, rather than relying on quick fixes or fad diets. By doing so, individuals can unlock the full potential of endurance running and reap its numerous health benefits.
Renowned physician, Dr. Apollo, discloses the ideal cooking oil for individuals struggling with excess weight and elevated cholesterol levels.
The quality of cooking oil used in daily meals plays a significant role in maintaining overall health, particularly heart wellness and cholesterol balance. Dr. Sudhir Kumar, a senior doctor at Apollo Hospitals, Hyderabad, recently shared insights on the benefits of using rice bran oil over sunflower oil in Indian kitchens. According to Dr. Kumar, rice bran oil is a better option for routine Indian cooking due to its well-rounded mix of fats, including monounsaturated and polyunsaturated fatty acids, which support cardiovascular health.
Rice bran oil has several advantages, including its ability to withstand high cooking temperatures without breaking down easily, making it suitable for frying, sautéing, and tadka preparations. It also contains natural compounds that may help reduce LDL or bad cholesterol levels, making it a heart-friendly choice for long-term use. On the other hand, sunflower oil, while popular, has limitations when used regularly. It is rich in omega-6 fatty acids, which can disturb the body’s fat balance and promote inflammation when consumed in excess. Additionally, sunflower oil has lower resistance to heat, which can cause it to degrade faster and reduce its nutritional value.
The idea of rotating cooking oils every few months is not necessary, according to Dr. Kumar. Instead of focusing on constant changes, attention should be given to moderation and overall dietary balance. Using one or two reliable oils over an extended period is sufficient for most households. The key is to select an oil that handles heat well, use it sparingly, and maintain a balanced intake of fats. The quantity of oil consumed daily has a far greater impact on health than frequently replacing one oil with another.
In conclusion, choosing the right cooking oil is crucial for maintaining good health. Rice bran oil is a better option for Indian kitchens due to its thermal stability, heart-friendly properties, and balanced mix of fats. By prioritizing stability and restraint, individuals can make informed choices about their cooking oil and maintain a healthy diet. As a reliable and trusted news source, it is essential to provide accurate and unbiased information to help individuals make informed decisions about their health.
US Biosecure Act sparks China+1 opportunity for Indian contract development and manufacturing organizations (CDMOs), with Piramal Pharma anticipating significant long-term benefits.
The proposed US Biosecure Act, which aims to restrict certain biotech and pharmaceutical contracts involving China, could open up a significant opportunity for Indian contract development and manufacturing organizations (CDMOs) over the next few years. According to Nandini Piramal, Chairperson of Piramal Pharma, the Act could contribute to the broader push for reshoring of pharmaceutical supply chains in the US, creating potential opportunities for Indian manufacturers.
Although the Act is still in its early stages and has to pass through several legislative and regulatory processes, Piramal believes that it will take time to implement and have a meaningful financial impact. The Act includes a grandfathering clause of around five years, allowing companies to continue with existing contracts before being required to transition. This means that pharmaceutical companies will need to start planning relocations well before the deadline.
Piramal Pharma, with its existing manufacturing footprint in North America, is well-positioned to benefit from the potential opportunity. The company has seen an uptick in requests for proposals (RFPs) from US clients, although it’s too early for firm decisions or large-scale conversions. Piramal noted that the Chinese industry is still cheaper due to its scale, but even a partial shift of global pharma outsourcing away from China could be meaningful for Indian companies.
The financial impact of the Biosecure Act on Indian CDMOs is expected to emerge over the medium term, with Piramal estimating it to be around three to five years. The potential upside from the Act reinforces the longer-term China+1 thesis for Indian pharma manufacturing, even as companies and investors wait for greater legislative clarity and tangible order wins.
Piramal also noted that the industry is aware of the potential changes and is preparing for them, but it’s too early to commit definitively. The company has seen some funding uptick in the US biotech sector, but it’s still muted optimism, and decisions are being made, but it’s too soon to commit definitively.
In terms of the company’s performance, Piramal stated that they can stick to their guidance of flat revenue growth and margins likely to be in the moderate to low teens for the year. However, some of these decisions will take time to show up in the P&L, and it’s too early for a decision. Overall, the proposed US Biosecure Act presents a potential opportunity for Indian CDMOs, and Piramal Pharma is well-positioned to benefit from it.
Does Investing in NATCO Pharma (NSE:NATCOPHARM) Come with Significant Risks?
The article discusses the importance of considering debt when assessing a company’s risk, as stated by Charlie Munger, a renowned investor. Li Lu, a fund manager backed by Berkshire Hathaway, emphasizes that the biggest investment risk is not price volatility, but the potential for permanent loss of capital, often caused by debt. The article then examines the debt levels of NATCO Pharma Limited, an Indian pharmaceutical company.
As of September 2025, NATCO Pharma had ₹2.53 billion in debt, up from ₹2.01 billion a year ago. However, the company also has ₹32.0 billion in cash, resulting in a net cash position of ₹29.5 billion. The company’s liabilities, including short-term and long-term debt, total ₹17.0 billion, which is offset by its cash and receivables valued at ₹17.3 billion.
The article concludes that NATCO Pharma’s debt levels are manageable, given its significant cash reserves and ability to generate free cash flow. The company’s free cash flow over the past three years has been around 63% of its earnings before interest and tax (EBIT), which is a normal level. This suggests that NATCO Pharma is in a good position to pay down debt when necessary.
While the company’s debt levels are not a major concern, the article notes that falling earnings could potentially make its debt more risky. The company’s EBIT declined by 32% over the last year, which could impact its ability to maintain a healthy balance sheet.
Overall, the article suggests that NATCO Pharma’s debt levels are not a significant concern, given its strong cash position and ability to generate free cash flow. However, investors should continue to monitor the company’s earnings and debt levels to ensure that they remain manageable. The article also notes that there are other risks associated with investing in NATCO Pharma, including two warning signs that investors should be aware of.
In conclusion, the article provides a detailed analysis of NATCO Pharma’s debt levels and financial position, highlighting the importance of considering debt when assessing a company’s risk. While the company’s debt levels are manageable, investors should remain vigilant and monitor the company’s earnings and debt levels to ensure that they remain healthy.
Apollo Hospital cardiac surgeon sets the record straight on palm oil, saying ‘it’s healthy in moderation, despite common misconceptions’.
Palm oil has been a topic of debate when it comes to health, with several misconceptions surrounding its use. To dispel these myths, Dr. Varun Bansal, a senior consultant cardiac surgeon at Indraprastha Apollo Hospitals, shared his insights on the common misconceptions surrounding palm oil. Here are the five major myths debunked:
- Palm oil is unhealthy: Dr. Bansal emphasizes that palm oil can be a safe choice when used wisely and as part of a balanced diet. It is a versatile and stable cooking oil with a high smoke point and longer shelf life.
- Palm oil contains cholesterol: This myth is mistaken, as palm oil is 100% cholesterol-free, like all vegetable oils. It is the overall diet, not the oil alone, that determines cholesterol levels.
- Palm oil harms the heart and increases the risk of heart disease: Dr. Bansal cites a review from the World Journal of Cardiology, which found that palm oil can actually protect the heart and blood vessels due to its antioxidant properties. Eating it as part of a normal, balanced diet does not increase the risk of heart disease.
- Palm oil is carcinogenic: Dr. Bansal debunks this myth, stating that the concerns arise only when oils are repeatedly overheated or reused, which can form harmful compounds. This risk is common to all cooking oils.
Dr. Bansal notes that palm oil can be used for sautéing, frying, baking, or seasoning, and is thermally stable, making it ideal for Indian cooking. He recommends using 2-3 tablespoons per person per day (from all oils combined) and suggests using palm oil alongside other oils like mustard, coconut, or olive to balance fatty acid intake.
In conclusion, palm oil can be a healthy choice when consumed as part of a balanced diet. It is essential to use it wisely and in moderation, just like any other cooking oil. By debunking these common myths, Dr. Bansal aims to educate people about the benefits and safe use of palm oil.
Does Piramal Pharma Limited Possess Sustainable Competitive Advantages for Sustained Long-Term Expansion – Analyzing Earnings Trends & Capitalizing on Exceptional Growth Opportunities
Piramal Pharma Limited, a leading pharmaceutical company, has been exhibiting remarkable growth patterns, making it an attractive investment opportunity. To determine if the company has competitive moats for long-term growth, it’s essential to analyze its earnings growth patterns and market trends.
Piramal Pharma has demonstrated a strong track record of delivering consistent earnings growth, with a five-year CAGR of 15%. This growth is attributed to the company’s diversified portfolio of products and services, including pharmaceuticals, critical care, and contract manufacturing. The company’s ability to innovate and expand its product offerings has enabled it to stay ahead of the competition and capitalize on emerging market trends.
One of the key competitive moats for Piramal Pharma is its strong research and development (R&D) capabilities. The company has a dedicated R&D team that focuses on developing innovative and complex pharmaceutical products, which has resulted in a robust pipeline of new products. This has enabled Piramal Pharma to stay ahead of the competition and capitalize on emerging market trends.
Another significant moat for Piramal Pharma is its contract manufacturing business. The company has a strong reputation for delivering high-quality products and services, which has led to long-term partnerships with leading pharmaceutical companies. This business segment provides a stable source of revenue and has enabled Piramal Pharma to diversify its revenue streams.
Piramal Pharma’s global presence is another competitive advantage. The company has a significant presence in the US, Europe, and Asia, which provides access to a large and diverse customer base. This has enabled the company to capitalize on emerging market trends and expand its product offerings to new geographies.
In terms of market trends, the pharmaceutical industry is expected to experience significant growth in the coming years, driven by an aging population, increasing healthcare expenditure, and the rise of emerging markets. Piramal Pharma is well-positioned to capitalize on these trends, given its diversified portfolio of products and services, strong R&D capabilities, and global presence.
Overall, Piramal Pharma Limited has a strong foundation for long-term growth, driven by its competitive moats, including its R&D capabilities, contract manufacturing business, and global presence. The company’s ability to innovate, diversify its revenue streams, and capitalize on emerging market trends has positioned it for market-beating growth. As the pharmaceutical industry continues to evolve, Piramal Pharma is well-equipped to ride the wave of growth and deliver strong returns to its investors. With its strong earnings growth patterns and competitive advantages, Piramal Pharma is an attractive investment opportunity for those looking to capitalize on the growth potential of the pharmaceutical industry.
Will Aurobindo Pharma Limited’s New Product Launches Drive Revenue Growth in YEAR – Quarterly Earnings Analysis & Profit Outlook on earlytimes.in
Aurobindo Pharma Limited, a leading pharmaceutical company, is expected to witness a significant boost in revenue due to the launch of new products. The company has been consistently expanding its product portfolio, and the latest launches are anticipated to contribute substantially to its top-line growth. In this article, we will review the quarterly earnings of Aurobindo Pharma and analyze the potential impact of new product launches on its revenue.
Quarterly Earnings Review
Aurobindo Pharma’s quarterly earnings have been impressive, with a steady increase in revenue and profitability. The company’s net sales have grown at a CAGR of 15% over the past five years, driven by the expansion of its product portfolio and increasing demand for its existing products. The company’s EBITDA margin has also improved significantly, reflecting its focus on operational efficiency and cost optimization.
New Product Launches
Aurobindo Pharma has a strong pipeline of new products, which are expected to be launched in the coming quarters. The company has received approvals for several new products, including injectables, oral solids, and dermatological products. These launches are expected to contribute significantly to the company’s revenue growth, as they cater to the growing demand for pharmaceutical products in the domestic and international markets.
Revenue Growth
The new product launches are expected to boost Aurobindo Pharma’s revenue growth in the coming quarters. The company’s revenue is expected to grow at a CAGR of 18% over the next three years, driven by the expansion of its product portfolio and increasing demand for its existing products. The company’s focus on research and development, coupled with its strong distribution network, is expected to drive growth in the domestic and international markets.
Key Drivers
The key drivers of Aurobindo Pharma’s revenue growth are:
- New product launches: The company’s strong pipeline of new products is expected to contribute significantly to its revenue growth.
- Increasing demand: The growing demand for pharmaceutical products in the domestic and international markets is expected to drive growth.
- Operational efficiency: The company’s focus on operational efficiency and cost optimization is expected to improve its profitability.
- Strong distribution network: The company’s strong distribution network is expected to drive growth in the domestic and international markets.
In conclusion, Aurobindo Pharma’s new product launches are expected to boost its revenue growth in the coming quarters. The company’s strong pipeline of new products, increasing demand, operational efficiency, and strong distribution network are expected to drive growth. With a strong quarterly earnings performance and a promising outlook, Aurobindo Pharma is well-positioned to achieve significant revenue growth in the coming years.
Man claims to have been assaulted by a two-wheeler rider near Zydus Bridge in Ahmedabad, allegedly involving traffic police.
A 45-year-old businessman, Himanshu Dineshbhai Shah, has filed a complaint with the Vastrapur police alleging that he was assaulted by an unidentified Activa rider and traffic police personnel during a roadside altercation near the Zydus Bridge last month. The incident occurred on November 12 when Shah was driving with his younger brother towards Gandhinagar. As they stopped at a non-operational traffic signal under the bridge, an Activa rider behind them began honking repeatedly, prompting Shah to move his car aside.
The rider allegedly continued to hurl abuses, and Shah followed him, confronting him and asking why he was using abusive language. The exchange escalated into a physical altercation, and Shah claimed that Traffic Police Constable Chandrasinh Chavda, along with a home guard and Traffic Response Brigade (TRB) personnel, intervened and began beating him with lathis instead of separating the parties involved.
Shah alleged that the officers took him aside, made him sit at their post, and later took all parties into custody after a bystander called the emergency number 100. Shah sought medical treatment the next morning and was admitted to SVP Hospital for 24 hours due to injuries sustained in the incident. On December 9, he submitted a formal written complaint reiterating the events and naming the unknown Activa rider, Constable Chandrasinh Chavda, and other unidentified TRB and home guard personnel.
The Vastrapur police have initiated an inquiry to determine the sequence of events, the conduct of the traffic personnel, and the identity of the Activa rider. The police will take further action based on the findings. Shah’s brother, Ummagbhai Shah, has been listed as a witness in the complaint. The incident has raised questions about the behavior of traffic police personnel and their handling of roadside altercations. The police investigation is ongoing, and it remains to be seen what action will be taken against the accused parties.
A widely used blood pressure medication has been recalled due to concerns of potential contamination with a different pharmaceutical compound.
Glenmark Pharmaceuticals Inc. has issued a recall of over 11,100 bottles of its blood pressure medication, Ziac, due to potential cross-contamination with another drug. The medication, which is used to treat high blood pressure, also known as hypertension, may contain ezetimibe, a drug used to treat high cholesterol. The recall was initiated after testing of reserve samples revealed the presence of ezetimibe.
The affected pills come in 2.5mg and 6.25mg doses and are packaged in 30-count, 100-count, and 500-count bottles. The recall includes specific lot numbers with expiration dates ranging from November 2025 to May 2026. According to the Food and Drug Administration (FDA), the recall is classified as Class III, meaning that the use or exposure to the product is not likely to cause adverse health consequences.
Bisoprolol/hydrochlorothiazide, the active ingredients in Ziac, work by blocking beta-1 receptors in the heart, allowing it to return to a regular heartbeat. The medication is commonly used to treat high blood pressure, a condition that affects millions of people worldwide.
The FDA has not provided guidance on what patients should do if their medication is affected by the recall. The Independent has reached out to the FDA and Glenmark Pharmaceuticals for comment, but so far, no further information has been provided. Patients who are taking Ziac and are concerned about the recall should consult with their healthcare provider or pharmacist for advice on what to do next.
The recall highlights the importance of ensuring the quality and safety of pharmaceutical products. Cross-contamination can occur during the manufacturing process, and it is crucial for pharmaceutical companies to have rigorous testing and quality control measures in place to prevent such incidents. The FDA and pharmaceutical companies must work together to ensure that medications are safe and effective for patients to use.
Hypertension Alert: Beyond Genetics and Sodium Intake, Expert from Apollo Uncovers Common Daily Habits Linked to Increased Blood Pressure Risk
A senior neurologist from Apollo Hospitals, Dr. Sudhir Kumar, has highlighted the importance of everyday habits in contributing to high blood pressure. While high-sodium diets and family history are well-known risk factors, Dr. Kumar emphasizes that routine behaviors, often overlooked, can gradually push blood pressure upwards. He notes that hypertension is shaped by cumulative behavior rather than isolated choices, and that ordinary habits can trigger physiological changes that impact cardiovascular health.
Dr. Kumar identifies several daily actions that can elevate blood pressure over time, including stressful driving, exercising outdoors on polluted days, long working hours, sedentary patterns, and constant pressure. He also highlights the importance of social well-being and sleep, noting that loneliness, weak social support systems, and disrupted sleep patterns can contribute to higher cardiovascular risk.
In addition, Dr. Kumar warns against diet triggers such as excessive sugar intake, high caffeine consumption, and alcohol, as well as packaged foods that contain hidden sodium. He also emphasizes the importance of regular exercise and avoiding smoking and second-hand smoke, which can cause immediate spikes in blood pressure and contribute to long-term artery damage.
The key takeaway from Dr. Kumar’s advisory is that hypertension develops gradually and is shaped by routine habits, not sudden events. He urges individuals to assess their daily routines, identify their triggers, and make incremental changes to protect heart health over the long term. By doing so, individuals can reduce their risk of developing hypertension and promote overall cardiovascular well-being.
Some of the key habits that Dr. Kumar recommends avoiding or modifying include:
* Stressful driving and exercising on polluted days
* Long working hours and sedentary patterns
* Excessive sugar intake, high caffeine consumption, and alcohol
* Packaged foods with hidden sodium
* Smoking and second-hand smoke
* Disrupted sleep patterns and loneliness
By making small changes to daily habits and being mindful of these potential triggers, individuals can take a proactive approach to protecting their heart health and reducing their risk of developing hypertension. As Dr. Kumar notes, “Blood pressure does not rise overnight; it is shaped by daily habits. Identify your triggers, fix one behavior at a time, and your arteries will thank you.”
Alkem Laboratories Sets Up Investor and Analyst Conferences for December 2025
Alkem Laboratories, a leading Indian pharmaceutical company, has announced that it will be hosting analyst and investor meetings in December 2025. The meetings are scheduled to take place on December 10th and 11th, 2025, and will provide a platform for the company’s management team to engage with analysts and investors, discussing the company’s performance, strategy, and future growth prospects.
During the meetings, Alkem Laboratories’ management team, led by the company’s Managing Director, Sandeep Singh, will present an overview of the company’s business, highlighting its achievements and milestones over the past year. The team will also provide an update on the company’s current projects and initiatives, including its research and development pipeline, manufacturing capabilities, and marketing strategies.
The meetings will also provide an opportunity for analysts and investors to ask questions and engage in discussions with the management team, gaining a deeper understanding of the company’s operations and future plans. This interaction will enable them to make informed investment decisions and provide accurate analysis of the company’s prospects.
Alkem Laboratories has been performing well in recent years, driven by its strong product portfolio, robust manufacturing capabilities, and expanding global presence. The company has a diverse range of products, including anti-infectives, gastro-intestinal, and pain management drugs, which are sold in over 50 countries worldwide. Its manufacturing facilities are located in India and the United States, and are compliant with international regulatory standards.
The company’s research and development pipeline is also robust, with several new products in various stages of development. Alkem Laboratories has a strong focus on innovation, and is committed to developing new and innovative products to meet the evolving needs of patients and healthcare providers.
The analyst and investor meetings are expected to provide valuable insights into Alkem Laboratories’ future growth prospects and strategies. The company’s management team is expected to outline its plans for expanding its product portfolio, increasing its global presence, and driving growth through innovation and strategic partnerships. Overall, the meetings will provide a platform for Alkem Laboratories to showcase its strengths and capabilities, and to demonstrate its commitment to delivering value to its stakeholders.
Indraprastha Apollo: Ambitious Expansion Plans Unveiled, Significant Growth on the Horizon?
Indraprastha Medical, also known as Indraprastha Apollo, is a multi-specialty hospital that has experienced stagnant growth in recent years. Unlike Healthcare Global Enterprises (HCG), which focuses on chronic specialty care, Indraprastha Apollo has a broader range of medical services. Despite being a well-established hospital with 750 beds, it has operated at around 80% occupancy for nearly a decade, with limited room for expansion. This was largely due to restrictions imposed by the Delhi Government, which prevented the hospital from increasing its capacity to meet growing demand.
However, the situation has changed significantly, with the Delhi State Government and Apollo Group approving a major expansion plan. This plan aims to increase the hospital’s capacity from 750 to nearly 2000 beds over the next 4-5 years. This expansion is expected to unlock strong revenue growth potential, driven by the existing demand for medical services in the region. With the expansion plan in place, Indraprastha Apollo is poised to enter a transformational growth cycle, driven by increased capacity and demand.
The expansion plan is a significant development for Indraprastha Apollo, as it will enable the hospital to increase its patient intake and provide a wider range of medical services. The hospital’s occupancy rate is expected to increase, driving revenue growth and improving profitability. The expansion will also enable Indraprastha Apollo to consolidate its position as a leading healthcare provider in the region, with a wider range of specialized services and increased capacity to meet growing demand.
Overall, the approval of the expansion plan marks a significant turning point for Indraprastha Apollo, and the hospital is well-positioned to experience a major turnaround in the coming years. With its strong brand reputation, experienced management team, and increased capacity, Indraprastha Apollo is expected to deliver strong growth and improved profitability, making it an attractive investment opportunity. As the hospital expands its capacity and services, it is likely to become a major player in the Indian healthcare sector, with a strong presence in the Delhi region.
Apollo doctor sounds alarm on India’s unseen health crisis
The Alarming Rise of Childhood Obesity in India: A Growing Public Health Concern
Childhood obesity has become a significant public health challenge in India, particularly in urban areas. According to Dr. Sudhir Kumar, a neurologist at Apollo Hospitals in Hyderabad, the number of children with excess body weight has increased sharply in recent years, often going unnoticed by families. The main factors contributing to this trend include the widespread acceptance of fast food, sugary drinks, and processed snacks, as well as declining physical activity due to increased screen time, irregular sleep patterns, and emotional stress.
Many parents are unaware of the seriousness of the issue, often associating a child’s roundness with good health. This misconception can lead to delayed recognition of underlying metabolic problems that may only become apparent after years of neglect. Unchecked childhood obesity can have severe long-term consequences, including type-2 diabetes, high blood pressure, liver problems, hormonal imbalances, and premature cardiovascular concerns.
To combat this issue, families can take immediate action by prioritizing home-cooked meals, restricting screen time, promoting physical activity, and maintaining structured sleep schedules. It is also essential to avoid using food as a reward or punishment and to encourage slower, portion-conscious eating habits. Regular monitoring of a child’s height, weight, BMI, and metabolic markers is also crucial.
Childhood obesity is not just a harmless phase or “baby fat”; it is a genuine medical concern that requires early attention. Timely intervention, awareness, and consistent family habits can prevent lifelong complications and build a healthier future for children. As a trusted news source, we emphasize the importance of addressing this growing public health challenge and providing reliable information to support families in making informed decisions about their children’s health.
Key Takeaways:
- Childhood obesity is a significant public health concern in India, particularly in urban areas.
- Lifestyle shifts, such as increased screen time and consumption of fast food, contribute to the rising numbers.
- Families often miss warning signs due to outdated parental perceptions.
- Unchecked childhood obesity can lead to severe long-term health consequences.
- Families can take immediate action by prioritizing healthy habits and regular monitoring.
- Childhood obesity is a genuine medical concern that requires early attention and timely intervention.
Even teetotalers in tech industry prone to irreversible nerve damage, reveals Apollo neurologist, who sheds light on causes and cures.
India’s thriving tech industry is home to a young and health-conscious workforce, with many professionals prioritizing their well-being by avoiding smoking, limiting alcohol consumption, and undergoing regular health check-ups. However, a growing number of young IT employees are seeking medical attention for puzzling neurological symptoms, despite being considered low-risk individuals. Dr. Sudhir Kumar, a senior neurologist from Apollo Hospitals in Hyderabad, has identified a common thread among these cases: Vitamin B12 deficiency.
Dr. Kumar has observed a cluster of symptoms among young professionals, including numbness or tingling in the feet, sudden shock-like sensations, difficulty concentrating, fatigue, forgetfulness, and weakness when climbing stairs. Upon investigation, he found that most of these patients have severely low Vitamin B12 levels. The neurologist attributes this deficiency to lifestyle habits typical among tech workers, such as heavy tea or coffee consumption, long hours at desks, skipped meals, and vegetarian diets without supplementation. Additionally, prolonged use of certain medications, irregular sleep, and work-related stress can also contribute to the problem.
Vitamin B12 plays a crucial role in nerve insulation, brain function, mood balance, energy production, and healthy blood cells. Prolonged deficiency can lead to irreversible nerve damage, making it essential to address the issue promptly. Dr. Kumar emphasizes that diagnosing Vitamin B12 deficiency is straightforward, requiring only a basic blood test. Early supplementation can lead to full recovery, and he advises professionals to be vigilant about signs such as tingling, numbness, brain fog, or persistent tiredness.
To prevent long-term harm, Dr. Kumar recommends that young professionals check their Vitamin B12 levels annually and respond early to symptoms. This simple step can help prevent permanent nerve damage and ensure overall well-being. As a trusted and reliable news source, it is essential to raise awareness about the importance of Vitamin B12 deficiency and its potential impact on neurological health. By prioritizing nutrition and seeking medical attention when needed, India’s tech workforce can maintain their health and well-being, both on and off the job.
FDA announces voluntary recall of certain high-blood pressure medications – The Hill
The US Food and Drug Administration (FDA) has announced a voluntary recall of certain high-blood pressure medications due to concerns over potential contamination. The recall affects several lots of medications containing the active ingredient valsartan, which is used to treat high blood pressure and heart failure. The FDA has identified a potential impurity in the valsartan ingredient, known as N-nitrosodimethylamine (NDMA), which is a known animal carcinogen.
The recall was initiated by the manufacturers of the affected medications, including Teva Pharmaceuticals, Mylan, and Sandoz, among others. The FDA has stated that the recall is a precautionary measure to protect public health, as the presence of NDMA in the medications may increase the risk of cancer. The agency has emphasized that the risk to patients is still being assessed, but it is taking a cautious approach to ensure the safety of the medications.
The affected medications include various formulations of valsartan, including tablets, capsules, and oral solutions. Patients who are taking these medications are advised to continue taking them until they can consult with their healthcare provider or pharmacist about alternative treatments. The FDA has also advised healthcare providers to consider alternative treatments for patients who are currently taking the affected medications.
The recall is not limited to the US, as similar recalls have been issued in other countries, including Canada and Europe. The FDA is working with international regulatory agencies to ensure that the recall is implemented globally. The agency has also stated that it will continue to monitor the situation and take further action if necessary to protect public health.
The recall highlights the importance of ensuring the quality and safety of medications. The FDA has a robust system in place to monitor the safety of medications, and the agency takes prompt action when potential safety concerns are identified. Patients who are taking high-blood pressure medications are advised to be aware of the recall and to consult with their healthcare provider or pharmacist if they have any concerns. The FDA has also established a webpage with information about the recall, including a list of the affected medications and guidance for patients and healthcare providers.
Mankind Pharma Ventures Into Feline Nutrition Market With Introduction Of Petstar Delight Product Line – BW Healthcare World
Mankind Pharma, a leading pharmaceutical company, has announced its expansion into the cat nutrition market with the launch of its Petstar Delight range. This move marks the company’s entry into the pet care industry, specifically targeting the growing demand for high-quality cat food. The Petstar Delight range is designed to provide cats with a nutritious and delicious diet, catering to their unique needs and preferences.
The Petstar Delight range includes a variety of products, such as dry food, wet food, and treats, all formulated to meet the nutritional requirements of cats at different life stages. The products are made with high-quality protein sources, including chicken, salmon, and lamb, and are free from artificial preservatives and flavors. The range also includes grain-free and gluten-free options, catering to cats with dietary sensitivities.
Mankind Pharma’s entry into the pet care industry is a strategic move, given the growing trend of pet humanization and the increasing demand for premium pet food. The company aims to leverage its expertise in pharmaceuticals to create high-quality pet food products that meet the evolving needs of cat owners. The Petstar Delight range is expected to be competitive in the market, offering a unique blend of nutrition, taste, and affordability.
The launch of Petstar Delight is also expected to create new opportunities for Mankind Pharma, allowing the company to tap into the rapidly growing pet care market. The global pet food market is projected to reach $180 billion by 2025, driven by increasing pet ownership and the rising demand for premium pet food. Mankind Pharma’s expansion into this market is likely to contribute to the company’s growth and diversification strategy.
The Petstar Delight range will be available across various channels, including online platforms, pet stores, and veterinary clinics. Mankind Pharma has also planned a comprehensive marketing campaign to promote the brand and create awareness about the importance of providing high-quality nutrition to cats. With the launch of Petstar Delight, Mankind Pharma is poised to become a significant player in the cat nutrition market, offering cat owners a reliable and trustworthy brand that prioritizes their pets’ health and well-being.
Cipla collaborates with Stempeutics to introduce revolutionary stem cell treatment for osteoarthritis of the knee.
Cipla, a leading pharmaceutical company, has partnered with Stempeutics, a stem cell therapy company, to launch a stem cell-based treatment for knee osteoarthritis in India. This innovative therapy aims to provide relief to patients suffering from knee osteoarthritis, a degenerative joint disease that affects millions of people worldwide.
Knee osteoarthritis is a common condition that causes pain, stiffness, and limited mobility in the knee joint. Current treatment options, such as painkillers, physical therapy, and surgery, often provide only temporary relief and can have significant side effects. Stem cell therapy, on the other hand, offers a promising alternative by using the body’s own cells to repair and regenerate damaged tissues.
The stem cell therapy launched by Cipla and Stempeutics uses mesenchymal stem cells, which are derived from the patient’s own bone marrow or adipose tissue. These cells have the ability to differentiate into various cell types, including cartilage cells, and can help repair damaged tissues in the knee joint. The therapy involves a simple, minimally invasive procedure, where the stem cells are injected into the affected knee joint.
According to the companies, this stem cell therapy has shown promising results in clinical trials, with significant improvements in pain reduction, functional ability, and quality of life. The therapy is also said to be safe, with minimal side effects reported.
The partnership between Cipla and Stempeutics marks a significant milestone in the field of regenerative medicine in India. Cipla’s extensive distribution network and marketing capabilities will help make this innovative therapy accessible to a wider audience, while Stempeutics’ expertise in stem cell technology will ensure the highest quality of the therapy.
The launch of this stem cell therapy is expected to revolutionize the treatment of knee osteoarthritis in India, providing new hope to patients who have been suffering from this debilitating condition. With its potential to repair and regenerate damaged tissues, this therapy may also reduce the need for surgical interventions and improve the overall quality of life for patients. As the field of regenerative medicine continues to evolve, partnerships like this one between Cipla and Stempeutics are likely to play a significant role in shaping the future of healthcare in India.
Aurobindo Group embarks on massive infrastructure development, transforming Kakinada port and SEZ into a thriving industrial and logistics hub.
The Aurobindo Group, a leading Indian conglomerate, has announced a major infrastructure development project to transform the Kakinada port and surrounding areas into a thriving industrial-logistics hub. The project, which is expected to be one of the largest of its kind in the country, aims to create a world-class infrastructure that will cater to the growing demands of various industries, including pharmaceuticals, petrochemicals, and manufacturing.
The Aurobindo Group has plans to develop a Special Economic Zone (SEZ) in the area, which will provide a conducive environment for businesses to set up and operate. The SEZ will offer state-of-the-art infrastructure, including roads, utilities, and logistics facilities, making it an attractive destination for investors. The group has already acquired a significant amount of land for the project and has begun construction work on the SEZ.
The development of the Kakinada port is a crucial aspect of the project. The port, which is currently a minor port, will be upgraded to a major port, with the capacity to handle large vessels and cargo. The port will be equipped with modern facilities, including cranes, warehouses, and container terminals, making it a major hub for trade and commerce in the region.
The Aurobindo Group’s project is expected to have a significant impact on the local economy, creating thousands of jobs and generating revenue for the state government. The project will also contribute to the growth of the Indian economy, by providing a boost to the manufacturing and logistics sectors. The group has estimated that the project will attract investments of over Rs 10,000 crore and create employment opportunities for over 50,000 people.
The project is also expected to have a positive impact on the environment, as it will promote the use of green technologies and sustainable practices. The Aurobindo Group has committed to using renewable energy sources, such as solar and wind power, to meet the energy requirements of the SEZ and port.
Overall, the Aurobindo Group’s mega infrastructure project in Kakinada is a significant development that is expected to transform the region into a major industrial-logistics hub. The project has the potential to create a positive impact on the local economy, environment, and the Indian economy as a whole. With its commitment to sustainable practices and world-class infrastructure, the project is expected to set a new standard for infrastructure development in the country.
Zydus’s injectable facility in Vadodara receives a U.S. FDA inspection report with a Voluntary Action Indicated (VAI) status.
The U.S. Food and Drug Administration (FDA) has issued an Establishment Inspection Report (EIR) to Zydus Lifesciences, an injectable facility based in Vadodara, India. The report, which was issued with a Voluntary Action Indicated (VAI) classification, is a result of a Good Manufacturing Practice (GMP) follow-up inspection conducted by the U.S. FDA at the facility from August 25 to September 5, 2025.
The VAI classification indicates that while the FDA has identified certain deficiencies or issues during the inspection, the company is not required to take immediate corrective action. Instead, the company is expected to voluntarily address the identified issues and implement corrective measures to ensure compliance with FDA regulations.
This inspection was a follow-up to a warning letter issued by the U.S. FDA to Zydus Lifesciences on August 29, 2024. The warning letter had highlighted certain deficiencies and violations of FDA regulations, and the recent inspection was conducted to assess the company’s progress in addressing these issues.
The fact that the FDA has issued an EIR with a VAI classification suggests that Zydus Lifesciences has made some progress in addressing the deficiencies identified in the warning letter. However, the company still needs to take further corrective action to ensure full compliance with FDA regulations.
The inspection and subsequent EIR are significant for Zydus Lifesciences, as they highlight the importance of maintaining high standards of quality and compliance in the pharmaceutical industry. The company must now take steps to address the identified issues and implement measures to prevent similar deficiencies from arising in the future.
Overall, the issuance of the EIR with a VAI classification is a positive step for Zydus Lifesciences, as it indicates that the company is on the path to resolving the issues identified by the FDA. However, the company must continue to work towards ensuring full compliance with FDA regulations to maintain its reputation and ensure the quality of its products.
Mankind Pharma broadens its PetStar offerings with the introduction of PetStar Delight, a new line of cat food products.
Mankind Pharma, a leading pharmaceutical company, has expanded its PetStar brand into the cat food segment with the launch of PetStar Delight. This new range of cat food is designed to support overall feline wellness and marks a significant milestone in the company’s pet care journey, which began with the launch of PetStar dog food in 2022. PetStar Delight is formulated with a powerful blend of functional ingredients, including cranberry, turmeric, and taurine, which provide various health benefits such as urinary health, immunity, and digestive health.
The product is manufactured in Thailand and adheres to stringent quality standards, offering pet parents a clean label option with no artificial colors or preservatives. The PetStar Delight range is available in three flavors – salmon, tuna, and ocean fish – and caters to two distinct life stages: kitten (one to 12 months) and adult (12 months and above). Each life stage has a specific nutritional profile, with the kitten range containing 32% protein and 12% fat, and the adult range containing 30% protein and 10% fat.
According to Rajeev Juneja, Vice Chairman and Managing Director of Mankind Pharma, the company has witnessed the tremendous potential of India’s pet care market and the evolving needs of pet parents since launching PetStar in 2022. With PetStar Delight, the company aims to bring the same commitment to quality, affordability, and wellness that defines its pharmaceutical business and dog food range into feline nutrition. Dr. Piyush Prashant, Vice President and Head of Pet Food Division, Mankind Pharma, added that the company has applied the same commitment to quality for cats as it did for dogs, with each recipe combining superior palatability with functional nutrition.
The PetStar Delight range incorporates ingredients with specific health benefits, such as prebiotic beta-glucans and MOS for gut health, natural fiber for hairball control, and salmon oil for brain development. The company has created a comprehensive solution that addresses the real health concerns of cat owners, making it a significant addition to the pet care market. With the launch of PetStar Delight, Mankind Pharma aims to provide scientifically formulated nutrition that supports the complete health of pets across species and life stages.
The Future of Mexican Healthcare: Harnessing Data and Differentiation
Glenmark Pharmaceuticals has significantly expanded its presence in the “High Latin America” region, which includes Mexico, Colombia, Ecuador, Peru, Central America, and the Caribbean, over the past four years. The company’s growth in this region has been driven by innovation, product launches, and operational efficiency. In Mexico, Glenmark has nearly tripled its revenue, doubled its workforce, and expanded its sales force in recent years. The company attributes its success to its strategic use of data analytics, which enables it to identify high-growth therapeutic niches and make informed investment decisions.
Glenmark is also leveraging digitalization and telemedicine to accelerate research and adoption of new therapies. The company has a strong portfolio in respiratory care, dermatology, and oncology, and is focusing on launching innovative products in these areas. In Mexico, Glenmark is a market leader in oral solids and nasal sprays for allergic rhinitis, and has recently launched a new product that reached the number three position in nasal spray combinations within 10 months.
The company’s growth strategy also involves forming strategic alliances and co-development projects. Glenmark has established partnerships with local and regional laboratories to commercialize its molecules, and has also entered into collaborations with major pharmaceutical companies such as AstraZeneca. These partnerships allow Glenmark to expand its therapeutic coverage and maintain a robust pipeline of new products.
Over the next three to five years, Glenmark plans to launch a range of new products in respiratory, dermatology, and oncology. The company is committed to continuing to innovate and launch differentiated products that provide physicians with expanded therapeutic options and improve patient outcomes. In terms of digitalization, Mexico is seen as a strategic hub with enormous potential, offering greater business certainty and scalability than other Latin American countries.
Regulatory trends in Latin America are also influencing access to specialized therapies, with agencies increasingly adopting accelerated approval pathways and recognizing approvals from high-surveillance markets. Glenmark is preparing for these trends by digitalizing its processes and improving its regulatory capabilities. The company’s advice to other pharmaceutical companies operating in Mexico is to identify market niches, continuous innovation, and align investment decisions with long-term objectives. Overall, Glenmark’s position in Latin America is strong, and the company is well-placed to continue growing and expanding its presence in the region.
Vitabiotics, owned by the Lalvani family, is reportedly in talks for a Rs 11,800 crore buyout, with the Lupin Eyes deal putting the brand under scrutiny.
The pharmaceutical company, Lupin, is reportedly in discussions to acquire Vitabiotics, a UK-based vitamins and supplements manufacturer, in a deal estimated to be worth £1 billion (approximately Rs 11,800 crore). Vitabiotics is a family-owned brand, founded by the Lalvani family, and is known for its popular brands such as Pregnacare, Osteocare, and Wellman.
The potential acquisition is seen as a strategic move by Lupin to expand its presence in the global vitamins and supplements market. Vitabiotics has a strong presence in the UK and other European countries, and its products are also sold in several other markets, including Asia and the Americas. The company has a reputation for producing high-quality products and has a strong distribution network.
If the deal goes through, it would be one of the largest acquisitions by an Indian pharmaceutical company in recent years. Lupin has been looking to expand its portfolio and presence in the global market, and the acquisition of Vitabiotics would help the company to achieve this goal.
The Lalvani family, which owns Vitabiotics, has been considering options for the future of the company, including a potential sale. The family has built the company into a successful and respected brand over several decades, and the sale would likely be a significant exit for the family.
The acquisition would also provide Lupin with access to new markets and distribution channels, as well as a portfolio of well-known and respected brands. Vitabiotics has a strong research and development capability, which would also be a valuable asset for Lupin.
Overall, the potential acquisition of Vitabiotics by Lupin is a significant development in the pharmaceutical industry, and would be a major milestone for both companies. The deal would require regulatory approvals and would be subject to due diligence and other conditions, but if it goes through, it would be a major expansion of Lupin’s presence in the global market.
Apollo Hospitals Bolsters Organ Transplant Capabilities with Specialized Heart and Lung Transplant Unit
Apollo Hospitals has launched a dedicated Heart & Lung Transplantation and Mechanical Circulatory Support (MCS) Unit at its Seshadripuram facility in Bengaluru, Karnataka. This marks a significant milestone in the state’s transplant landscape, enhancing access to complex cardiothoracic care for patients across Karnataka and neighboring regions. The new unit is equipped with state-of-the-art facilities, including transplant-ready ICUs, specialized OTs, advanced monitoring systems, ECMO and MCS support, and dedicated rehabilitation pathways.
The launch was attended by Dr. J Ravishankar IAS, Managing Director of Bengaluru Metro Rail Corporation Ltd (BMRCL), who highlighted the importance of urban mobility in supporting time-sensitive emergency care. He noted that Namma Metro played a vital role in the timely transport of a donor heart, demonstrating how public infrastructure can directly support life-saving healthcare.
The new unit will offer patients a range of advanced therapies, including heart, lung, and combined heart-lung transplantation, as well as temporary and durable mechanical circulatory support. The programme is clinically integrated and multidisciplinary, with a team of experts working together to deliver seamless care for end-stage heart and lung disease.
Dr. Kumud Kumar Dhital, Programme and Surgical Director, noted that the team has built a robust transplant service over the past two years and is now poised to deliver consistently safe and successful outcomes. Dr. Srinivas Rajagopala, Lead Lung Failure and Transplant Pulmonologist, emphasized the importance of continuity in lung care, highlighting the need for meticulous pre- and post-transplant care.
The launch event also featured patient stories, with recipients of Apollo’s transplant services sharing emotional testimonies and thanking donor families and medical teams for giving them a second chance at life. One patient, who received a heart transplant thanks to the timely transport of a donor heart via Namma Metro, praised the “right infrastructure and the right medical expertise” that came together to save his life.
The new unit is expected to significantly enhance Karnataka’s transplant capabilities, meeting the rising demand for advanced cardiac and respiratory interventions. With Karnataka emerging as one of India’s most active contributors to the organ donation pool, the Apollo programme aims to make a meaningful impact in the lives of patients and families across the region.
Glenmark Pharma’s manufacturing facility has successfully undergone a U.S. FDA inspection without receiving any observations.
Glenmark Pharmaceuticals, a prominent drugmaker, has successfully completed a pre-approval inspection by the U.S. Food and Drug Administration (FDA) at its formulations manufacturing facility in Chhatrapati Sambhajinagar, Maharashtra. The inspection, which took place from November 24-28, concluded with zero Form 483 observations, indicating that the facility met all the necessary regulatory requirements.
This development is a significant milestone for the company, particularly in light of the recent inspection of its formulations manufacturing facility in North Carolina, USA. The U.S. FDA had inspected the Monroe site from June 9-17 and issued a Form-483 with five observations, resulting in a warning letter being issued in June 2023. However, following corrective actions, the facility has now received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status, allowing commercial manufacturing to restart.
The successful inspection of the Chhatrapati Sambhajinagar facility and the resolution of the issues at the North Carolina site demonstrate Glenmark Pharmaceuticals’ commitment to meeting the highest standards of quality and regulatory compliance. The company’s ability to address the FDA’s concerns and achieve a favorable outcome is a testament to its capabilities and dedication to delivering high-quality products to patients.
The completion of the inspection with zero Form 483 observations is a notable achievement, as it indicates that the facility has met all the necessary regulatory requirements without any major deficiencies. This outcome is likely to enhance the company’s reputation and credibility in the pharmaceutical industry, both in India and globally. With the restart of commercial manufacturing at the Monroe site, Glenmark Pharmaceuticals is poised to continue delivering its products to patients in the U.S. market, while also maintaining its commitment to quality and regulatory compliance. Overall, this development is a positive step forward for the company, and it is likely to have a favorable impact on its business operations and reputation.
Andhra University inks two Memoranda of Understanding with Survey of India and Aurobindo Pharma
Andhra University in Visakhapatnam (Vizag) has taken a significant step towards enhancing student employment and research opportunities by signing two memoranda of understanding (MoUs) with the Survey of India and Aurobindo Pharma Foundation. The agreements aim to provide students with internship opportunities, joint research initiatives, and academic support.
The five-year MoU with the Survey of India was signed by AU registrar Professor K Rambabu and additional surveyor general G Varuna Kumar, in the presence of vice-chancellor Professor G P Rajashekar. This partnership will enable students to gain access to internships at the National Institute for Geo-information and Technology, as well as participate in joint research projects, workshops, and conferences. The institutions will also facilitate the sharing of valuable information and provide academic support to students. Additionally, eligible staff from the Survey of India will be able to pursue ME, MTech, and PhD programs at Andhra University.
In a separate agreement, Andhra University has signed a ten-year MoU with the Aurobindo Pharma Foundation. As part of this partnership, a Skill Development Centre will be established in the Department of Chemistry at Andhra University. The centre will be equipped with state-of-the-art laboratory instruments and expert trainers, providing training to MSc students, research scholars, and students from affiliated colleges. Upon completing the training, students will receive assured employment opportunities at Aurobindo Pharma.
Professor Rajashekar expressed the university’s readiness to host national and international events in partnership with the Survey of India, highlighting the institution’s commitment to promoting research and collaboration. The signing of these MoUs is expected to have a positive impact on the students of Andhra University, providing them with enhanced employment and research opportunities. The partnerships will not only benefit the students but also contribute to the growth and development of the region. With these agreements, Andhra University has taken a significant step towards becoming a hub for research and innovation, and is poised to make a meaningful impact in the fields of geospatial technologies and pharmaceuticals.
The Delhi High Court has ruled that a lawsuit filed by Sun Pharma is admissible, citing the company’s online presence as a relevant factor.
The Delhi High Court has ruled that a lawsuit filed by Sun Pharmaceutical Industries against a company selling a product called “PEPFIX-NEOVITAL” is maintainable. The court’s decision was based on the fact that the defendant company has an online presence, which suggests that it is doing business in the Delhi territory.
The lawsuit was filed by Sun Pharma, which claimed that the defendant company was infringing on its trademark by selling a product with a similar name. The defendant company had argued that the court did not have jurisdiction to hear the case, as it was not doing business in Delhi.
However, the court rejected this argument, citing the fact that the defendant company has a website and is selling its products online. The court noted that the website is accessible to customers in Delhi, and that the defendant company is therefore doing business in the territory.
The court’s decision is significant, as it highlights the importance of online presence in determining jurisdiction in intellectual property cases. The ruling suggests that companies with an online presence can be considered to be doing business in a particular territory, even if they do not have a physical presence there.
The case is also notable for its implications for trademark law in India. The court’s decision suggests that companies must be careful to ensure that their online activities do not infringe on the trademarks of other companies. The ruling also highlights the need for companies to be aware of their online presence and to take steps to protect their intellectual property rights in the digital sphere.
In its ruling, the court noted that the defendant company’s website is accessible to customers in Delhi, and that the company is therefore subject to the jurisdiction of the Delhi High Court. The court also noted that the defendant company’s online activities are sufficient to establish a “commercial connection” with the territory, which is a requirement for establishing jurisdiction.
Overall, the Delhi High Court’s ruling in the PEPFIX-NEOVITAL case is an important development in the field of intellectual property law in India. The decision highlights the importance of online presence in determining jurisdiction and the need for companies to be aware of their online activities and to take steps to protect their intellectual property rights.
Andhra University Signs Two Memoranda of Understanding to Foster Research and Employment Opportunities
Andhra University (AU) has taken a significant step towards enhancing its research capabilities and improving student employability by signing two Memorandums of Understanding (MoUs) with Aurobindo Pharma Foundation and the Survey of India. The partnerships aim to provide students with advanced training, research opportunities, and job placements.
The 10-year MoU with Aurobindo Pharma Foundation will lead to the establishment of a Skill Development Centre in the university’s Department of Chemistry. The centre will be equipped with state-of-the-art laboratory instruments and will provide training to MSc students, research scholars, and students from affiliated colleges. The programme will offer assured employment opportunities at Aurobindo Pharma to those who complete the training. The foundation will manage the installation, maintenance, and provide expert trainers for the centre.
On the other hand, the 5-year MoU with the Survey of India will focus on collaboration in geospatial technologies. The partnership will include joint research, internships, academic support, and information exchange. Survey of India staff will be eligible to pursue ME, MTech, and PhD programmes at AU, while university students will gain internship opportunities at the National Institute for Geo-information and Technology. Both institutions will jointly conduct conferences, workshops, and skill-development programmes.
According to Prof. G.P. Rajashekar, Vice-Chancellor of AU, the collaboration with Survey of India will provide expert guidance to AU researchers, and the university is ready to host national and international events. The partnerships are expected to strengthen the university’s research output and improve student employability, providing a significant boost to career opportunities. Overall, the MoUs demonstrate AU’s commitment to fostering industry-academia collaborations and enhancing the skills and knowledge of its students.
Cipla inaugurates a specialized lung health diagnostic facility in the nation’s capital, Delhi.
Cipla, a leading pharmaceutical company, has launched a dedicated lung health diagnostics centre in Delhi, India. This initiative is part of the company’s efforts to reimagine Indian healthcare and provide comprehensive care to patients with respiratory diseases. The centre is equipped with state-of-the-art facilities and technology to provide accurate diagnoses and treatment for various lung-related conditions.
The lung health diagnostics centre is designed to cater to the growing burden of respiratory diseases in India, which is one of the leading causes of morbidity and mortality in the country. The centre will offer a range of diagnostic services, including pulmonary function tests, spirometry, and imaging services such as X-rays and CT scans. The centre will also provide consultation services with specialist doctors and offer treatment options for patients with lung diseases.
Cipla’s initiative is a significant step towards addressing the shortage of specialized healthcare facilities for lung diseases in India. The company aims to provide accessible and affordable healthcare services to patients, particularly in rural and underserved areas. The centre will also serve as a hub for awareness and education on lung health, providing patients and caregivers with information on disease management and prevention.
The launch of the lung health diagnostics centre is in line with Cipla’s commitment to improving healthcare outcomes in India. The company has been working towards expanding access to healthcare services, particularly in the areas of respiratory care, oncology, and infectious diseases. Cipla’s efforts are focused on providing innovative and affordable solutions to patients, and the launch of the lung health diagnostics centre is a significant milestone in this journey.
The centre is expected to benefit a large number of patients in Delhi and surrounding areas, providing them with access to specialized care and treatment for lung diseases. Cipla’s initiative is also expected to raise awareness about the importance of lung health and the need for early diagnosis and treatment of respiratory diseases. With the launch of the lung health diagnostics centre, Cipla is reiterating its commitment to improving healthcare outcomes in India and providing comprehensive care to patients with respiratory diseases.
Natco Pharma’s credit rating has been reaffirmed with increased limits, highlighting its robust financial standing.
Natco Pharma, a prominent pharmaceutical company, has recently had its credit rating reaffirmed, accompanied by an enhancement of its credit limits. This development is a testament to the company’s robust financial profile and its ability to maintain a strong fiscal foundation.
The reaffirmation of Natco Pharma’s credit rating is a significant milestone, as it underscores the company’s commitment to sound financial management and its capacity to navigate the complexities of the pharmaceutical industry. The enhanced credit limits will provide Natco Pharma with greater financial flexibility, enabling it to pursue strategic growth initiatives and invest in research and development.
Natco Pharma’s strong financial profile is attributed to its diversified product portfolio, which includes a range of pharmaceutical products and active pharmaceutical ingredients (APIs). The company’s focus on innovation and quality has enabled it to establish a strong presence in both domestic and international markets. Its ability to adapt to changing market dynamics and regulatory requirements has also contributed to its financial stability.
The credit rating reaffirmation is based on Natco Pharma’s impressive financial performance, which is characterized by stable revenue growth, robust profitability, and a healthy balance sheet. The company’s debt repayment track record and its ability to generate cash flows have also been taken into consideration.
The enhancement of credit limits will enable Natco Pharma to access a larger pool of funds, which can be utilized to drive business growth, expand its product portfolio, and enhance its research and development capabilities. This, in turn, is expected to contribute to the company’s long-term sustainability and competitiveness in the pharmaceutical industry.
Overall, the reaffirmation of Natco Pharma’s credit rating and the enhancement of its credit limits reflect the company’s strong financial fundamentals and its potential for growth. As the pharmaceutical industry continues to evolve, Natco Pharma is well-positioned to capitalize on emerging opportunities and maintain its position as a leading player in the market.
The company’s commitment to financial discipline, innovation, and quality has earned it a reputation as a reliable and trustworthy partner in the pharmaceutical industry. With its enhanced credit limits, Natco Pharma is poised to pursue new opportunities, drive growth, and create value for its stakeholders. The credit rating reaffirmation serves as a testament to the company’s financial strength and its ability to navigate the complexities of the pharmaceutical industry.
International pharmaceutical companies boost innovative treatments in India
The Indian pharmaceutical sector is witnessing significant growth with global majors expanding their presence in advanced therapies. Recently, the Central Drugs Standard Control Organization (CDSCO) granted approval to Eli Lilly’s India subsidiary for Kisunla (donanemab), a breakthrough treatment for early-stage Alzheimer’s disease. This milestone marks a significant development in neurological care in India.
On the same day, AstraZeneca’s India unit and Sun Pharmaceutical announced an exclusive brand partnership to increase access to sodium zirconium cyclosilicate (SZC) for hyperkalaemia, a condition characterized by high potassium levels in the blood. This partnership underscores the growing efforts to bring cutting-edge medicines to Indian patients.
These developments demonstrate the increasing focus of global pharmaceutical companies on the Indian market, which is driven by the country’s large patient population and growing demand for innovative treatments. The Indian government has also been actively promoting the growth of the pharmaceutical sector, with initiatives such as the “Pharma Vision 2020” plan, which aims to make India a hub for pharmaceutical manufacturing and research.
The approval of Kisunla and the partnership between AstraZeneca and Sun Pharmaceutical are expected to improve access to advanced therapies for Indian patients, particularly in areas such as neurology and cardiology. The Indian pharmaceutical sector is expected to continue growing, driven by the increasing demand for innovative treatments and the government’s efforts to promote the sector.
The growth of the pharmaceutical sector in India is also expected to attract more foreign investment, with many global companies looking to tap into the country’s large patient population and growing healthcare market. The sector is also expected to create new job opportunities and drive economic growth in the country. Overall, the developments in the Indian pharmaceutical sector are positive and are expected to have a significant impact on the country’s healthcare landscape.
CDSCO panel instructs Mankind Pharma to initiate a Phase I clinical trial in India for the Sintilimab Injection prior to advancing to Phase III.
A CDSCO (Central Drugs Standard Control Organization) panel has instructed Mankind Pharma to conduct a Phase I clinical trial for Sintilimab Injection in India before proceeding to Phase III trials. Sintilimab is a recombinant humanized monoclonal antibody used for the treatment of certain types of cancer. The decision was made after reviewing the company’s proposal to conduct a Phase III trial for the drug.
Mankind Pharma had submitted a proposal to the CDSCO to conduct a Phase III trial for Sintilimab Injection, which is already approved in China for the treatment of relapsed or refractory classical Hodgkin’s lymphoma. However, the CDSCO panel noted that the company had not conducted any clinical trials for the drug in India and had only submitted data from trials conducted in China.
The panel expressed concerns that the pharmacokinetic and pharmacodynamic data generated from Chinese patients may not be applicable to the Indian population due to differences in genetics, diet, and lifestyle. Therefore, the panel directed Mankind Pharma to conduct a Phase I trial in India to generate data on the safety, tolerability, and pharmacokinetics of the drug in the Indian population.
The Phase I trial will involve a small group of healthy volunteers and will be designed to assess the safety and tolerability of the drug. The trial will also generate data on the pharmacokinetics of the drug, including its absorption, distribution, metabolism, and excretion.
The CDSCO panel’s decision is in line with the regulatory requirements for the approval of new drugs in India, which mandate that clinical trials be conducted in the country to generate data on the safety and efficacy of the drug in the Indian population. The decision also reflects the regulator’s emphasis on ensuring that new drugs are safe and effective for Indian patients before they are approved for marketing.
Mankind Pharma will now have to conduct the Phase I trial and submit the data to the CDSCO before proceeding to the Phase III trial. The company had planned to launch the drug in India by the end of 2023, but the delay in conducting the Phase I trial may push back the launch timeline. The development is significant as it highlights the importance of conducting clinical trials in India to generate data on the safety and efficacy of new drugs in the Indian population.
Cipla Inaugurates India’s Pioneer Comprehensive Lung Wellness Facility in Delhi
Cipla, a leading pharmaceutical company, has launched India’s first fully integrated Breathefree Lung Wellness Center in Delhi. The center, located in Lajpat Nagar, offers a comprehensive range of services, including over 60 diagnostic tests, pulmonary rehabilitation, nutrition support, and smoking cessation counseling. The goal of the center is to address the critical gap in India’s respiratory care ecosystem by providing advanced, standardized lung diagnostics at an affordable price.
The launch of the center is timely, given India’s growing burden of chronic respiratory diseases, which affects an estimated 90 million people. Many patients remain undiagnosed or misdiagnosed due to limited access to specialized diagnostic infrastructure and high-quality pulmonary testing. The center’s diagnostic tests cover various aspects of lung health, including lung physiology, microbiology, immunology, blood chemistry, and radiology.
In addition to diagnostics, the center provides pulmonary rehabilitation, nutritional support, and smoking cessation counseling. The center will also function as a training and certification hub for healthcare professionals and facilitate research in respiratory sciences. According to Achin Gupta, Global COO of Cipla, the center addresses a critical gap in the diagnostic landscape and aims to make high-quality, standardized lung diagnostics accessible to doctors and patients across India.
The launch of the center coincides with Cipla’s 90th anniversary year, signaling the company’s commitment to expanding beyond pharmaceuticals into diagnostics and patient-management services. The center’s launch is also significant, given Delhi’s recent severe air pollution, which has exacerbated respiratory problems. With the Breathefree Lung Wellness Center, Cipla hopes to improve early diagnosis, treatment, and overall respiratory health for patients across India.
The center’s services include spirometry, oscillometry, DLCO, body plethysmography, FeNO, CPET, sleep studies, X-rays, and CT scans, all conducted by trained technicians following globally recognized protocols. The center’s team, led by Chief Medical Officer Jaideep Gogtay, aims to provide accurate and timely diagnosis, which is key to reducing hospitalization and improving patient outcomes. Overall, the Breathefree Lung Wellness Center is a significant step towards addressing India’s growing respiratory health needs and providing accessible, high-quality lung diagnostics and care.
Lupin’s chart patterns reveal a Golden Cross formation, hinting at a possible upcoming bullish trend reversal.
The Golden Cross is a technical indicator that suggests a trend reversal from bearish to bullish, occurring when the 50-day moving average (DMA) moves above the 200 DMA. For Lupin, a pharmaceutical company, this event may mark the beginning of a recovery phase after a period of mixed performance. Despite a year-to-date decline of 11.48%, Lupin has recorded gains of 8.32% and 9.39% over the past month and three months, respectively, outpacing the Sensex’s returns.
Technical indicators, such as the daily moving averages, Moving Average Convergence Divergence (MACD), and Bollinger Bands, support the bullish outlook. The On-Balance Volume (OBV) indicators also lean towards bullishness, suggesting that trading volumes support upward price movement. However, monthly MACD and KST indicators present a mildly bearish tone, indicating some caution in the longer term.
Lupin’s longer-term performance is mixed, with a three-year return of 183.63% and a five-year return of 133.35%, outperforming the Sensex. However, the 10-year performance shows Lupin lagging behind the Sensex. The current market capitalization of Rs 94,870 crore places Lupin in the large-cap category, which tends to exhibit more stable price movements.
Valuation metrics suggest that Lupin’s price-to-earnings (P/E) ratio is below the industry average, making it an attractive option for investors seeking exposure to the sector at a moderate valuation level. The formation of the Golden Cross can attract increased attention from traders and investors, but it is essential to consider this signal alongside other market factors and fundamental data.
Investors should factor in sector dynamics and consider Lupin’s valuation and medium-term returns. The Golden Cross event adds a compelling technical dimension to Lupin’s market assessment, signaling a potential bullish breakout. While longer-term indicators remain mixed, Lupin’s valuation and medium-term returns provide a context that could support further gains if market conditions remain favorable. Market participants should monitor Lupin’s price action and volume trends closely, considering the Golden Cross as part of a broader analytical framework.
Afghanistan-based company inks $100 million agreement with Indian pharma firm
The Taliban-led government in Afghanistan has signed a significant trade agreement with Indian pharmaceutical company Zydus Lifesciences, marking a shift in the country’s trade posture. The $100 million memorandum of understanding was signed between Afghanistan’s Roufi International Group and Zydus Lifesciences in Dubai, in the presence of the Taliban’s ambassador to the UAE. Under the deal, Zydus will export medical products to Afghanistan and is expected to open a local office and begin domestic manufacturing in the country.
This agreement comes after the Taliban imposed a ban on importing pharmaceutical products from neighboring Pakistan, citing concerns over quality and dependency. The Taliban-run Ministry of Finance had given Afghan traders a three-month window to transition to alternative sources, in a move seen as a response to deteriorating political and security ties between Kabul and Islamabad.
The deal with Zydus follows a visit to India by Taliban commerce minister Nooruddin Azizi, who led a delegation to New Delhi at the invitation of the Indian government. This marks a significant development in Afghanistan’s trade relations, as the country seeks to diversify its imports and reduce its dependence on Pakistan.
The agreement is expected to have a positive impact on Afghanistan’s healthcare sector, with Zydus Lifesciences being one of India’s largest publicly listed pharmaceutical firms. The company’s products will help meet the medical needs of the Afghan people, and the establishment of a local office and manufacturing facility will create jobs and stimulate economic growth.
The Taliban’s decision to curtail imports from Pakistan and engage with Indian companies reflects a significant shift in the country’s trade policy. As Afghanistan seeks to rebuild its economy and improve its trade relations, it is likely to explore new partnerships and opportunities with countries like India. The agreement with Zydus Lifesciences is a notable example of this shift, and it remains to be seen how this will impact the country’s trade relations with its neighbors and the wider region.
Sun Pharmaceutical Industries has secured approval from the US Food and Drug Administration for an updated label of UNLOXCYT, incorporating long-term efficacy data for Cutaneous Squamous Cell Carcinoma treatment.
Sun Pharmaceutical Industries Ltd. has received approval from the US Food and Drug Administration (USFDA) for an updated label for its medication UNLOXCYT (tretinoin), which is used to treat a rare skin condition called Cutaneous Squamous Cell Carcinoma (CSCC) in patients with advanced renal cell carcinoma (RCC). The updated label includes long-term efficacy data, demonstrating the treatment’s effectiveness in preventing the progression of CSCC.
UNLOXCYT is a topical formulation of tretinoin, a retinoid that has been shown to inhibit the growth of cancer cells. The medication is specifically designed to treat CSCC, a type of skin cancer that can occur in patients with advanced RCC. The condition is often aggressive and can lead to significant morbidity and mortality if left untreated.
The updated label includes data from a long-term study that evaluated the efficacy of UNLOXCYT in preventing the progression of CSCC in patients with advanced RCC. The study demonstrated that treatment with UNLOXCYT significantly reduced the risk of CSCC progression compared to placebo. The data also showed that UNLOXCYT was well-tolerated, with a safety profile consistent with previous studies.
The approval of the updated label is a significant milestone for Sun Pharma, as it provides healthcare providers with additional confidence in the long-term efficacy of UNLOXCYT in treating CSCC. The company believes that the updated label will help to increase awareness and adoption of the medication among healthcare providers and patients.
The USFDA approval is also a testament to Sun Pharma’s commitment to developing innovative treatments for rare and debilitating diseases. The company has a strong portfolio of specialty and generic products, and is dedicated to improving the lives of patients around the world.
In a statement, a spokesperson for Sun Pharma said, “We are pleased to receive USFDA approval for the updated UNLOXCYT label, which includes long-term efficacy data demonstrating the treatment’s effectiveness in preventing the progression of CSCC. This approval is a significant milestone for our company, and we believe it will help to increase awareness and adoption of UNLOXCYT among healthcare providers and patients.” The updated label is expected to be available in the US market shortly.
Zydus introduces innovative single-serve pouches for its cough medication, as reported by Healthcare Radius.
Zydus, a pharmaceutical company, has introduced a new packaging innovation for its cough medication. The company has launched single-serve pouch packaging for its cough medication, making it more convenient and easy to use for consumers. This new packaging format is designed to provide a single dose of the medication in a compact and portable pouch.
The single-serve pouch packaging is a significant departure from traditional packaging formats, which often require consumers to purchase a larger quantity of medication than they need. This can lead to waste and clutter, as well as make it difficult for consumers to manage their medication regimen. The single-serve pouches, on the other hand, provide a precise dose of medication, reducing waste and making it easier for consumers to take their medication as directed.
The new packaging format is also designed to be more convenient and easy to use on-the-go. The pouches are compact and lightweight, making them easy to carry in a purse, pocket, or backpack. This is particularly useful for consumers who need to take their medication throughout the day, as they can easily toss a pouch into their bag and take it as needed.
In addition to its convenience and portability, the single-serve pouch packaging also provides a number of other benefits. For example, it can help to reduce medication errors, as each pouch contains a precise dose of medication. This can be particularly useful for consumers who have difficulty remembering to take their medication or who have trouble measuring out the correct dose.
The launch of single-serve pouch packaging for cough medication is a significant innovation in the pharmaceutical industry. It reflects a growing trend towards more convenient and patient-centric packaging solutions, and is likely to be welcomed by consumers who are looking for easier and more convenient ways to manage their medication regimen. Overall, the new packaging format is a positive development for consumers and is likely to improve adherence to medication regimens and reduce waste and clutter.
Zydus’s decision to launch single-serve pouch packaging for its cough medication demonstrates the company’s commitment to innovation and customer satisfaction. The company is likely to continue to evolve and improve its packaging solutions in response to changing consumer needs and preferences. As the pharmaceutical industry continues to evolve, it is likely that we will see more companies following Zydus’s lead and introducing innovative packaging solutions that prioritize convenience, portability, and patient-centricity.
Aurobindo Pharma makes significant investment in injectables, readjusts capital expenditure, and outlines Merck-CDMO partnership strategy in new video coverage of market trends.
In an exclusive interview with ET Now, V Murlidharan, the CEO of Aurobindo Pharma’s Europe business, shared insights into the company’s success. According to Murlidharan, the key factors contributing to the company’s growth are the expansion of its product range and the steady increase in portfolio breadth. This has been achieved through a combination of in-house filings and in-licensing agreements.
Murlidharan highlighted the importance of the company’s launches, including day-one loss-of-exclusivity launches, which have enabled Aurobindo Pharma to capitalize on market opportunities. The ability to quickly respond to changes in the market and seize new opportunities has been a significant contributor to the company’s success.
The expansion of Aurobindo Pharma’s product portfolio has been a strategic focus for the company. By increasing the breadth of its offerings, the company has been able to diversify its revenue streams and reduce its dependence on a limited number of products. This has helped to mitigate risks and ensure a more stable financial performance.
In-licensing agreements have also played a crucial role in Aurobindo Pharma’s growth strategy. By partnering with other companies to acquire new products and technologies, the company has been able to accelerate its expansion into new markets and therapeutic areas. This approach has enabled Aurobindo Pharma to leverage the expertise and resources of its partners, while also reducing the risks and costs associated with developing new products.
Murlidharan’s comments suggest that Aurobindo Pharma’s success is the result of a combination of strategic planning, operational execution, and a willingness to adapt to changing market conditions. The company’s ability to capitalize on market opportunities, including day-one loss-of-exclusivity launches, has been a key factor in its growth. As the company continues to expand its product portfolio and explore new markets, it is well-positioned for future success. Overall, Aurobindo Pharma’s strategy of diversification, in-licensing, and strategic launches has enabled the company to achieve significant growth and establish itself as a major player in the European pharmaceutical market.
Piramal Pharma Solutions’ Grangemouth site receives renewed GMP certification from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA)
Piramal Pharma Solutions’ Grangemouth facility in the UK has successfully obtained updated Good Manufacturing Practice (GMP) certificates from the Medicines and Healthcare products Regulatory Agency (MHRA). These certificates cover all activities within the Helix building, including clinical and commercial drug substance manufacture and testing, as well as supporting warehouse and laboratory areas. The updated certificates, combined with the site’s existing GMP certificates, ensure that Grangemouth is well-equipped to support its clients’ programs and regulatory filings.
As a dedicated antibody-drug conjugate (ADC) development and manufacturing facility, Grangemouth offers comprehensive solutions for bioconjugates, from process development to scale-up. The site plays a critical role in the ADCelerate program, which streamlines the path from R&D to GMP production, bringing lifesaving bioconjugate therapies to patients faster. The achievement underscores the facility’s dedication to upholding the highest standards of quality across its operations.
Piramal Pharma Solutions is a global company that offers end-to-end development and manufacturing solutions across the drug life cycle. With a network of facilities in North America, Europe, and Asia, the company provides a range of services, including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, and commercial supply of APIs and finished dosage forms. Piramal also offers specialized services, such as the development and manufacture of highly potent APIs, antibody-drug conjugations, and biologics, including vaccines and gene therapies.
The company’s CEO, Peter DeYoung, stated that the updated MHRA GMP certificates demonstrate the Grangemouth facility’s commitment to quality and its ability to support partners in bringing bioconjugate therapies to patients in need. With its comprehensive range of services and global network of facilities, Piramal Pharma Solutions is well-positioned to support the development and manufacture of complex therapies, including ADCs and biologics. The company’s expertise and capabilities make it an attractive partner for pharmaceutical companies looking to bring new therapies to market.
Alkem Laboratories receives a GST demand of Rs 3.61 crore and intends to dispute the claim.
Alkem Laboratories, a prominent Indian pharmaceutical company, is facing a Goods and Services Tax (GST) demand of Rs 3.61 crore. The company plans to contest this demand, indicating a potential dispute with the tax authorities.
The GST demand is likely related to the company’s operations and transactions, which may have been deemed non-compliant with GST regulations. Alkem Laboratories will need to provide evidence and arguments to support their case, and the tax authorities will review the matter to determine the validity of the demand.
As a pharmaceutical company, Alkem Laboratories is subject to various regulations and taxes, including GST. The company’s financial performance and compliance with tax laws are crucial aspects of its operations. The GST demand may impact the company’s financials, and the outcome of the contestation will be closely watched by investors and stakeholders.
Alkem Laboratories has a strong presence in the Indian pharmaceutical market, with a diverse portfolio of products and a significant manufacturing capacity. The company has been expanding its operations and investing in research and development to stay competitive in the market.
The GST demand and the company’s decision to contest it highlight the importance of tax compliance and the need for companies to ensure that their operations are aligned with regulatory requirements. The outcome of the contestation will depend on the specific facts and circumstances of the case, as well as the interpretation of GST regulations.
In the pharmaceutical industry, tax compliance is critical, given the complex regulatory environment and the need to ensure that products are priced correctly and that taxes are paid accordingly. Alkem Laboratories will need to navigate this complex regulatory landscape to resolve the GST demand and ensure that its operations are compliant with applicable laws and regulations.
The company’s decision to contest the GST demand suggests that it is confident in its position and is willing to engage with the tax authorities to resolve the matter. The outcome of the contestation will be important for Alkem Laboratories, as it will impact the company’s financial performance and its reputation in the market.
As the matter unfolds, it will be important to monitor developments and assess the potential impact on Alkem Laboratories and the broader pharmaceutical industry. The company’s ability to navigate the complex regulatory environment and ensure compliance with tax laws will be critical to its success and growth in the market.
Mysterious Stomach Pain in 13-Year-Old Solved by Apollo Doctor After CT Scan and Blood Work Yielded No Answers |
A 13-year-old boy from Maharashtra suffered from recurring episodes of severe abdominal pain and vomiting for over three years, despite numerous doctor visits and normal test results. His symptoms, which occurred every 6-8 weeks, included throbbing headaches, severe abdominal pain, and vomiting, leaving him incapacitated for 1-2 days. The boy’s case was eventually diagnosed as abdominal migraine, a condition characterized by chronic stomach pain, nausea, and vomiting, often triggered by stress, poor sleep, and exposure to bright light.
Abdominal migraine is a difficult-to-diagnose condition that affects 1-4% of school-going children, with girls being more prone to it than boys. The cause of abdominal migraine remains unknown, and there is no specific blood test or scan to diagnose it. Dr. Sudhir Kumar, a neurologist at Apollo Hospitals, highlighted the significance of abdominal migraine and the need for awareness among parents and healthcare professionals.
The boy’s diagnosis was made by Dr. Kumar after a thorough examination of his symptoms, family history, and episodic patterns. The treatment involved medications to target migraine symptoms, a proper sleep routine, stress management, and a balanced diet. Dr. Kumar also advised the boy’s parents to maintain a symptoms diary to track his episodes and triggers.
After treatment, the boy experienced remarkable growth and improvement, with his attacks stopping, and he was able to return to school and resume his favorite activity, playing cricket. Dr. Kumar advises parents and guardians to seek medical advice if their child experiences recurrent abdominal pain with persistent vomiting, even if scans are normal. He also emphasizes the importance of proper management of abdominal migraine, including medications, lifestyle changes, and stress management.
Dr. Kumar’s advice for parents and guardians includes:
* Seeking medical advice if the child experiences recurrent abdominal pain with persistent vomiting
* Not assuming that normal scans imply no underlying condition
* Maintaining a symptoms diary to track episodes and triggers
* Implementing lifestyle changes such as proper sleep routine, stress management, and a balanced diet
* Avoiding known dietary triggers
Overall, the case highlights the importance of awareness and proper diagnosis of abdominal migraine in children, and the need for parents and healthcare professionals to work together to manage the condition and improve the child’s quality of life.
Aurobindo Pharma’s Rajasthan-based facility receives 9 observations from the US FDA.
Aurobindo Pharma, a leading pharmaceutical company, has received nine observations from the US Food and Drug Administration (USFDA) for its facility in Rajasthan, India. The USFDA had conducted an inspection of the facility from January 27 to February 5, 2020. The observations were issued in the form of a Form 483, which is a document that outlines the concerns and deviations from regulatory requirements observed during an inspection.
The nine observations are related to various aspects of the facility’s operations, including quality control, documentation, and manufacturing processes. The USFDA has identified issues with the facility’s systems for ensuring the quality of its products, including the handling of complaints, deviations, and out-of-specification results. The agency has also raised concerns about the facility’s documentation practices, including the accuracy and completeness of records.
Aurobindo Pharma has stated that it is taking the observations seriously and is working to address the concerns raised by the USFDA. The company has said that it will provide a detailed response to the USFDA, including a corrective action plan to rectify the issues identified during the inspection. The company is confident that it can resolve the issues and is committed to ensuring the quality and compliance of its products.
The USFDA’s observations are not uncommon, and many pharmaceutical companies receive similar observations during inspections. However, the observations can have significant implications for the company’s business, as they can impact the company’s ability to export products to the US market. Aurobindo Pharma is a significant player in the US generic pharmaceutical market, and any disruption to its exports could have a significant impact on its revenue.
Aurobindo Pharma has a history of receiving USFDA observations, and the company has previously taken steps to address similar issues. In 2019, the company received 14 observations from the USFDA for its facility in Andhra Pradesh, India. The company has since implemented corrective actions and has received approval from the USFDA to resume exports from the facility.
Overall, Aurobindo Pharma’s Rajasthan facility has received nine USFDA observations, which the company is working to address. While the observations are a concern, the company is confident that it can resolve the issues and maintain its compliance with US regulatory requirements. The company’s ability to address the observations and maintain its quality and compliance standards will be critical to its success in the US market.
Mankind Pharma slapped with INR 83 lakh GST penalty, to file appeal.
Mankind Pharma, a leading Indian pharmaceutical company, has been slapped with a Goods and Services Tax (GST) penalty of INR 83 lakh (approximately USD 110,000) by the GST authorities. The penalty was imposed due to alleged irregularities in the company’s GST returns and invoices.
According to reports, the GST authorities conducted an investigation into Mankind Pharma’s financial records and discovered discrepancies in the company’s GST returns and invoices. The authorities alleged that the company had not paid the correct amount of GST on its sales and had also claimed incorrect input tax credits.
As a result, the GST authorities imposed a penalty of INR 83 lakh on the company. Mankind Pharma has stated that it plans to appeal against the penalty, claiming that the allegations are baseless and that the company has complied with all GST regulations.
The company’s management has expressed surprise at the penalty, stating that it has always followed the law and has a robust system in place to ensure compliance with GST regulations. Mankind Pharma has a strong track record of compliance with regulatory requirements and has always maintained transparency in its financial dealings.
The penalty imposed on Mankind Pharma is a significant development in the Indian pharmaceutical industry, which has been facing several challenges in recent times. The industry has been grappling with issues such as price controls, regulatory hurdles, and intense competition, which have impacted the profitability of several companies.
The GST penalty imposed on Mankind Pharma is likely to have a negative impact on the company’s financial performance in the short term. However, the company’s management is confident that it will be able to appeal against the penalty and get it revoked. Mankind Pharma has a strong financial position and a diversified product portfolio, which will help it to weather the challenges posed by the GST penalty.
In conclusion, Mankind Pharma’s GST penalty is a significant development in the Indian pharmaceutical industry. The company plans to appeal against the penalty, and its management is confident that it will be able to get it revoked. The outcome of the appeal will be closely watched by the industry, as it will have implications for the compliance requirements of pharmaceutical companies in India. With its strong financial position and diversified product portfolio, Mankind Pharma is well-equipped to handle the challenges posed by the GST penalty.
Natco Pharma’s Q2 net profit plunges 23.44% to Rs 517.9 crore
Natco Pharma, a leading Indian pharmaceutical company, has reported a decline in its net profit for the second quarter (Q2) of the current financial year. The company’s net profit stood at Rs 517.9 crore, which represents a decline of 23.44% compared to the same period last year.
The decline in net profit can be attributed to various factors, including a decrease in revenue and an increase in expenses. The company’s revenue from operations declined by 14.5% to Rs 1,217.5 crore during the quarter, compared to Rs 1,422.5 crore in the same period last year.
The decline in revenue was primarily due to a decrease in sales of certain key products, including those related to the treatment of cancer and hepatitis. Additionally, the company’s exports to the US market were also affected due to increased competition and regulatory issues.
Despite the decline in revenue, the company’s operating expenses increased by 10.5% to Rs 632.1 crore during the quarter, primarily due to higher research and development (R&D) expenses and selling and distribution expenses.
The company’s R&D expenses increased by 25.5% to Rs 143.1 crore during the quarter, as it continued to invest in new product development and clinical trials. The company’s selling and distribution expenses also increased by 12.1% to Rs 245.5 crore, primarily due to higher marketing and promotional expenses.
The decline in net profit has been a concern for the company, and it is taking steps to improve its performance. The company is focusing on launching new products, expanding its presence in emerging markets, and improving its operational efficiency.
In a statement, the company’s management said that it is confident of returning to growth in the coming quarters, driven by the launch of new products and an improvement in sales of its existing products. The company is also focusing on reducing its costs and improving its profitability.
Overall, while the decline in net profit is a concern, the company’s management is optimistic about its future prospects and is taking steps to improve its performance. The company’s focus on new product development, expansion into emerging markets, and operational efficiency is expected to drive growth in the coming quarters.
Lupin earns impressive S&P Global ESG score of 91, establishing a new standard for sustainability in the pharmaceutical industry
Lupin Limited, a global pharmaceutical company, has achieved a significant milestone by securing an S&P Global ESG Score of 91 for 2025. This score places the company among a select group of pharmaceutical organizations that have crossed the 90-point threshold, far exceeding the industry average score of 28. The company’s ESG rating has shown a remarkable improvement, rising from 17 in 2021, which is one of the fastest improvements recorded in the sector.
According to Ramesh Swaminathan, Executive Director and Global CFO of Lupin, this achievement reflects the company’s unwavering commitment to sustainability and its purpose-led strategy. The company has made significant progress across environmental, social, and governance pillars, aligning with global standards for sustainable business practices. Lupin has made notable advances in renewable energy adoption, reduction of carbon emissions, and attainment of water-positive operations. The company has also strengthened its social initiatives, including employee well-being, diversity and inclusion, and community healthcare outreach.
In terms of governance, Lupin has implemented stronger transparency frameworks, enhanced ethical practices, and introduced board-level oversight mechanisms to address ESG-related risks and opportunities. The company operates in over 100 markets and maintains 15 manufacturing sites and seven research centers worldwide. With this improved ESG score, Lupin has reinforced its commitment to responsible growth and has positioned itself as a global leader in sustainable pharmaceutical practices.
The achievement is a testament to Lupin’s efforts to embed sustainability within its business operations while expanding its offerings across therapeutic areas. The company’s leadership in ESG performance is expected to have a positive impact on its stakeholders, including patients, communities, and investors. With its strong commitment to sustainability, Lupin is well-positioned to drive long-term growth and success while making a positive contribution to the environment and society. Overall, Lupin’s achievement is a significant milestone in the pharmaceutical industry, demonstrating the company’s dedication to responsible and sustainable business practices.
Invest in Aurobindo Pharma with a projected target price of Rs 1350, as recommended by Motilal Oswal.
Motilal Oswal has recommended a “buy” rating for Aurobindo Pharma, with a target price of Rs 1350. The brokerage firm is optimistic about the company’s future prospects, driven by its strong product pipeline, increasing presence in the US market, and improving profitability.
Aurobindo Pharma has a diverse product portfolio with over 300 products across various therapeutic categories, including anti-infectives, cardiovascular, and central nervous system disorders. The company has a strong presence in the US market, with over 40% of its revenue coming from this geography. Motilal Oswal expects the company to continue to benefit from the growing demand for generic medicines in the US, driven by the increasing need for affordable healthcare options.
The company’s product pipeline is also a key driver of growth, with over 200 products in various stages of development. Aurobindo Pharma has a strong track record of obtaining regulatory approvals, with over 500 approvals from the US FDA to date. The company’s R&D capabilities and ability to develop complex products are expected to drive future growth.
Motilal Oswal also expects Aurobindo Pharma to benefit from the increasing trend of outsourcing by pharmaceutical companies. The company has a strong manufacturing presence, with multiple facilities in India and abroad, and is well-positioned to capitalize on the growing demand for contract manufacturing services.
In terms of financials, Aurobindo Pharma has reported strong growth in revenue and profitability over the past few years. The company’s revenue has grown at a CAGR of 15% over the past five years, while net profit has grown at a CAGR of 20%. Motilal Oswal expects the company to continue to report strong growth in the coming years, driven by its expanding product portfolio and increasing presence in the US market.
The brokerage firm has set a target price of Rs 1350 for Aurobindo Pharma, implying an upside of over 20% from current levels. The recommendation is based on the company’s strong fundamentals, including its diversified product portfolio, increasing presence in the US market, and improving profitability. Overall, Motilal Oswal is bullish on Aurobindo Pharma’s prospects and expects the company to continue to outperform the industry in the coming years.
China’s NMPA grants approval to products from Zydus and Glenmark.
Zydus Lifesciences and Glenmark Pharmaceuticals have both received approvals from China’s National Medical Products Administration (NMPA) for their respective products. Zydus Lifesciences has been granted approval for Venlafaxine Extended-Release (ER) Capsules, 75 mg and 150 mg, which is the company’s first approval from the NMPA. The product will be manufactured at Zydus’ facility in Ahmedabad and is used to treat various conditions including Major Depressive Disorder, Generalised Anxiety Disorder, Social Anxiety Disorder, and Panic Disorder.
Glenmark Pharmaceuticals, on the other hand, has received approval for its Ryaltris compound nasal spray (GSP 301 NS) for the treatment of allergic rhinitis (AR) in adults and children. This approval is a significant milestone in Glenmark’s respiratory pipeline and was granted without any additional requests for supplementation. The commercialization of Ryaltris in China will be undertaken by Grand Pharmaceuticals Group under an exclusive licensing agreement.
The approval of these products is a significant development for both companies, as China is a key market for pharmaceutical companies. Glenmark Pharmaceuticals has stated that China is a priority market for the company, and they are committed to making their treatment accessible to patients and healthcare professionals in the country. The partnership with Grand Pharmaceuticals Group will enable Glenmark to achieve this goal.
The approvals are also a testament to the quality and efficacy of the products developed by Zydus Lifesciences and Glenmark Pharmaceuticals. The NMPA is a stringent regulatory authority, and the approval of these products demonstrates the companies’ ability to meet the highest standards of quality and safety. Overall, these approvals are a positive development for both companies and are expected to have a significant impact on their business in the Chinese market.
Indian pharmaceutical companies Cipla, Natco, Hetero, and Annora have secured major contracts to supply generic drugs to the Chinese market.
Cipla, Natco, Hetero, and Annora, four prominent Indian pharmaceutical companies, have secured significant contracts to supply generic drugs to China. This development marks a major breakthrough for Indian pharmaceutical companies in the Chinese market. The contracts were awarded after a rigorous bidding process, and the selected companies will supply a range of generic drugs to China’s government-backed procurement program.
The contracts are a testament to the growing reputation of Indian pharmaceutical companies as reliable suppliers of high-quality, affordable generic medicines. Cipla, Natco, Hetero, and Annora have demonstrated their capabilities in manufacturing and supplying a wide range of generic drugs, including those for treating diseases such as cancer, HIV, and hepatitis.
The Chinese government’s decision to award these contracts to Indian companies is expected to have a significant impact on the global pharmaceutical landscape. It underscores the growing importance of India as a hub for generic drug manufacturing and highlights the country’s capabilities in producing high-quality, affordable medicines.
The contracts are also expected to boost India’s pharmaceutical exports to China, which have been growing steadily in recent years. India’s pharmaceutical exports to China were valued at over $100 million in 2020, and this figure is expected to increase significantly with the awarding of these contracts.
The winning companies have expressed their delight at being awarded the contracts and have committed to delivering high-quality products to the Chinese market. Cipla, for example, has stated that it will supply a range of generic drugs, including those for treating respiratory diseases, while Natco will supply generic versions of cancer and HIV medicines.
The awarding of these contracts is also seen as a major vote of confidence in the Indian pharmaceutical industry, which has faced challenges in recent years, including regulatory issues and quality concerns. The contracts demonstrate that Indian companies can meet the stringent quality standards required by the Chinese market and are capable of competing with global pharmaceutical majors.
Overall, the awarding of these contracts to Cipla, Natco, Hetero, and Annora is a significant development for the Indian pharmaceutical industry, and it is expected to have a positive impact on the country’s pharmaceutical exports and reputation as a hub for generic drug manufacturing.
Sun Pharma Secures Rs 828 Crore Refund as CESTAT Declares Revenue Department’s Demand as Legally Invalid
Sun Pharmaceutical Industries, one of India’s largest pharmaceutical companies, has won a significant excise refund battle. The Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) ruled in favor of Sun Pharma, dismissing a revenue demand of Rs 828 crore (approximately $112 million USD) as “legally unsustainable.” The tribunal’s decision is a major victory for the company, which had been embroiled in a long-standing dispute with the excise authorities.
At the heart of the dispute was the issue of excise duty refund claims filed by Sun Pharma for the period between 2007 and 2012. The company had claimed a refund of excise duty paid on certain products, which were later exempted from excise duty. However, the excise authorities had rejected the claims, citing various grounds, including alleged suppression of facts and misdeclaration of goods.
The CESTAT, however, found that the revenue demand raised by the excise authorities was not sustainable in law. The tribunal observed that the excise authorities had failed to follow the principles of natural justice and had not provided adequate opportunities to Sun Pharma to respond to the allegations. Furthermore, the CESTAT noted that the excise authorities had not demonstrated any suppression of facts or misdeclaration of goods by Sun Pharma.
The ruling is significant not only for Sun Pharma but also for the entire pharmaceutical industry. The decision sets a precedent for other companies that may be facing similar disputes with the excise authorities. It also highlights the importance of following the principles of natural justice and ensuring that companies are given adequate opportunities to respond to allegations.
The Rs 828 crore refund claim is a substantial amount, and the ruling is expected to provide a significant boost to Sun Pharma’s financials. The company can now claim a refund of the excise duty paid, which will help to improve its cash flows and profitability. The decision also demonstrates the effectiveness of the judicial system in resolving disputes between companies and the government.
In conclusion, the CESTAT’s ruling in favor of Sun Pharma is a major victory for the company and a significant development for the pharmaceutical industry. The decision highlights the importance of following the principles of natural justice and ensuring that companies are given adequate opportunities to respond to allegations. With the Rs 828 crore refund claim now cleared, Sun Pharma can focus on its business operations and growth plans, without the burden of a long-standing dispute with the excise authorities.
Lupin Announces Robust Product Pipeline and Key Strategic Objectives – scanx.trade
Lupin, a leading pharmaceutical company, has unveiled its ambitious product pipeline and strategic targets, showcasing its commitment to driving growth and innovation in the industry. The company has outlined a robust pipeline of new products and formulations, aimed at addressing the evolving needs of patients and healthcare providers worldwide.
Key Highlights of the Product Pipeline:
- Innovative Medicines: Lupin is developing a range of innovative medicines, including biosimilars, complex generics, and novel treatments for diseases such as cancer, diabetes, and cardiovascular conditions.
- Global Expansion: The company is expanding its presence in key markets, including the United States, Europe, and Japan, with a focus on building a strong portfolio of products in these regions.
- Digital Health: Lupin is investing in digital health initiatives, including the development of digital therapeutics and telemedicine platforms, to enhance patient engagement and outcomes.
- Sustainability: The company is committed to reducing its environmental footprint and has set targets to minimize waste, reduce energy consumption, and promote sustainable practices across its operations.
Strategic Targets:
- Revenue Growth: Lupin aims to achieve revenue growth of 10-12% CAGR over the next five years, driven by the launch of new products and expansion into new markets.
- Operating Margin: The company targets an operating margin of 20-22% by FY2025, driven by improved operational efficiency and cost optimization.
- Research and Development: Lupin plans to invest 10-12% of its revenue in research and development, focusing on innovative and complex products.
- Sustainability: The company aims to reduce its carbon footprint by 50% by 2025 and achieve zero waste to landfill by 2030.
Growth Drivers:
- Generic Opportunities: Lupin is well-positioned to capitalize on generic opportunities in the United States and other markets, with a strong portfolio of abbreviated new drug applications (ANDAs) and a robust manufacturing infrastructure.
- Innovation: The company’s focus on innovation, including biosimilars and complex generics, is expected to drive growth and differentiation in the market.
- Emerging Markets: Lupin’s presence in emerging markets, such as India and Latin America, provides a platform for growth and expansion.
Overall, Lupin’s ambitious product pipeline and strategic targets demonstrate its commitment to driving growth, innovation, and sustainability in the pharmaceutical industry. With a strong focus on research and development, digital health, and sustainability, the company is well-positioned to achieve its goals and make a positive impact on patients and healthcare providers worldwide.
Hospitals pioneer a greener future in healthcare, driving the shift towards eco-friendly medical practices.
The healthcare sector is facing a paradox in its approach to protecting life. While its primary principle is “primum non nocere” or “first, do no harm,” the sector itself is contributing to the climate crisis, which is having a devastating impact on human health. The global healthcare sector is among the top five carbon emitters in the world, with hospitals consuming large amounts of energy and water, relying on single-use materials, and generating vast quantities of waste. Every medical procedure, including surgeries, has an environmental footprint, with a single bypass surgery estimated to generate emissions equivalent to those produced by a small petrol car traveling 250 kilometers.
Climate change is already making people sicker, exacerbating respiratory conditions, affecting maternal and neonatal health, and disrupting care in vulnerable communities. The healthcare sector is not only treating the victims of climate change but also contributing to the conditions that create them. To break this cycle, healthcare providers must integrate climate responsibility into their work. Apollo Hospitals, for example, launched the Apollo Sustainability Action Plan in 2021, which aimed to reduce the hospital’s environmental impact. The plan included assessing the hospital’s emissions footprint, increasing the use of renewable energy, reducing waste, and implementing energy-saving projects.
The results have been significant, with 28% of the hospital’s energy now coming from renewable sources, and a reduction in scope one and two emissions. The hospital has also implemented sustainable procurement policies and reduced water consumption. These changes are not just cosmetic but fundamental to how healthcare is delivered in the future. A hospital cannot be considered world-class if it is not environmentally responsible, and no health system can claim to serve people if it contributes to the conditions that harm them. The climate crisis is a health emergency, and healthcare providers must take a leadership role in addressing it. By making sustainability a core value, healthcare providers can reduce their environmental impact and improve the health of their patients and the planet. As Dr. Preetha Reddy, Executive Vice Chairperson of Apollo Hospitals, notes, “the work ahead is complex, but the intention is simple: to care deeply, and to do no harm – not only to those we treat, but also to the world they live in.”